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Preface 
The patient (T.K.), was first diagnosed as having a partial 
hypoxanthine-guanine phosphoribosyltransferase deficiency in 1978 
when he was 20 years old. At presentation, he complained of a 
colicky1oi~-pain which radiated into his groin, and that ~e had 
had dark urine for a month. He was shown to have haematuria and 
urate crystalluria, and had a serum urate of 0.8mmol/l (reference 
range 0.12-0.Smmol/l). The diagnosis was confirmed by 
demonstrating a haemolysate hypoxanthine-guanine 
phosphoribosyltransferase activity of SSOµU/mg Hb (reference 
range 1680-2480µU/mg Hb). Studies to determine whether the low 
hypoxanthine-guanine phosphoribosyltransferase activity was 
caused by an altered Km of the enzyme for one of its substrates, 
showed that there was substrate inhibition of the enzyme activity 
by hypoxanthine. 
This thesis examines the patient and the variant HPRT at three 
levels. 
Firstly, a detailed and comprehensive study of the the 
kinetic properties of the variant enzyme was made. The novel 
feature of the kinetics is the presence of substrate inhibition 
by the purine bases, with a true Ki value for hypoxanthine of 
80+- 20µM, and a normal value for the true Km. The pattern of 
substrate inhibition is characteristic of that associated with 
the formation of a dead-end complex a'nd double inhibition 
experiments indicate that the form of this complex is 
enzyme-hypoxanthine-PPi. These unusual kinetic properties 
provided an opportunity to study the order of substrate binding 
in a way not possible for the normal enzyme and showed an ordered 
sequential reaction mechanism. Some limited protein-structural 
studies were performed and showed an altered electrophoretic 
mobility for the variant enzyme in non-denaturing gels. 
Secondly, the purine metabolic pathways in cultured cells, 
derived from T.K., from a patient with the Lesch-Nyhan syndrome, 
and from normal individuals, were studied. The cells were 
labelled with precursors of the de novo or of the salvage 
pathways, usually in the presence of a reference label, and 
sometimes in the presence of inhibitors of the various steps in 
the purine metabolic pathways. Hypoxanthine salvage was about 
10% of that of control cultures. The growth of cells in a 
variety of selective media was also studied. 
Thirdly, as physician in charge of T.K., I could monitor the 
progress of his hyperuricaemia and observe the effects of therapy 
throughout the duration of this project. 
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Fig. 1. Outline of purine metabolism. 
1) Amidophosphoribosyltransferase; 2) PP-ribose-P synthetase 
3) hypoxanthine-guanine phosphoribosyltransferase; 4) adenine 
phosphoribosyltransferase; 5) adenosine deaminase; 6) 5'-
nucleotidase; 7) purine nucleoside phosphorylase; 8) xanthine 
oxidase; 9) adenosine-5'-monophosphate deaminase; 10) 
guanosine-5'-monophosphate synthetase; 11) inosine-5'-
monophosphate deaminase; 12) adenylosuccinate synthetase. 
1. INTRODUCTION 
1.1. Purine metabolism 
Purine nucleotides are synthesised from two sources (Fig. 1): 
1) by the de nova synthetic pathway from the small precursor 
molecules, PP-ribose-P, glutamine, formate, aspartate and 
bicarbonate. The adenine and guanine nucleotides are formed from 
IMP, the first nucleotide product of the de novo pathway~ 
2 
2) by the activity of the phosphoribosyltransferases, 
hypoxanthine-guanine phosphoribosyltransferase (HPRT) and adenine 
phosphoribosyltransferase (APRT), from pre-formed purine bases and 
PP-ribose-P. 
1.2. Regulation of purine metabolism 
Purine synthesis de novo is regulated by feedback inhibition on 
the sequential reactions catalysed by PP-ribose-P synthetase and 
by amidophosphoribosyltransferase (ART), (Wyngaarden and Kelley 
1983). The activities of both these enzymes are modified by the 
concentrations of the ribonucleotide end-products of the de novo 
pathway (Fox and Kelley 1972, Holmes et al 1973). There are two 
molecular forms of ART (Holmes et a1 1973), a high molecular 
weight (270 000) inactive form and a low molecular weight (133 000) 
active form. The interconversion of the inactive form to the 
active form is stimulated by the presence of PP-ribose-P, while 
3 
AMP and GMP have the opposite effect (Holmes et a1 1973). The 
ribonucleotides inhibit the activity of PP-ribose-P synthetase (Fox 
and Kelley 1972), and may therefore lower the concentration of 
PP-ribose-P, with a further reduction in the amount of active ART. 
The regulatory role of PP-ribose-P has been further established by 
observations that have shown that high intracellular levels of 
PP-ribose-P are associated with an increased rate of synthesis 
de novo, while low levels are associated with a reduced rate of 
synthesis de novo (Kelley and Wyngaarden 1983). The nucleotides, 
GMP and AMP, regulate their rate of synthesis from IMP by feedback 
inhibition on the IMP dehydrogenase and adenylosuccinate synthetase 
activities, respectively (Mager and Magasanik 1960, Wyngaarden and 
Greenland 1963). The formation of GMP requires ATP hydrolysis at 
the GMP synthetase step, while the formation of adenylosuccinate 
requires GTP hydrolysis, therefore high intracellular levels of either 
of these nucleotide triphosphates will favour the formation of the 
other. However, GTP appears to have the major role in 
determining the relative rate of interconversion of IMP to either 
GMP or AMP (Kelley and Wyngaarden 1983). High levels of GTP 
inhibit the formation of XMP from IMP, and stimulate 
adenylosuccinate synthetase activity, while low levels favour the 
formation of GMP from IMP. Further control may be found at the 
level of the phosphoribosyltransferases, which are inhibited by 
their respective nucleotide monophosphates (Henderson 1968). 
1.3. Purine synthesis as a cyclic process 
Purine synthesis has been described as being a cyclic process with 
PP-ribose-P (or ribose) acting as a carrier on which the purine 
ring is assembled (Mapes and Krebs 1978). The PP-ribose-P can be 
released from IMP by the pyrophosphorylase action of HPRT. 
HPRT may therefore play a role in channelling IMP to 
PP-ribose-P synthesis and hypoxanthine to purine excretion, 
especially in uricotelic animals. 
1.4. Deficiencies in purine metabolising enzymes 
In recent years deficiencies in a number of purine metabolising 
enzymes have been recognised. The clinical and biochemical 
consequences of these enzyme deficiencies have increased the 
understanding of the role of these enzymes in purine metabolism, 
and has led to a greater insight into purine metabolism in 
general. 
1.4.1. Adenosine deaminase deficiency 
A deficiency in the activity of adenosine deaminase (ADA) has 
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been shown to result in an altered function in T-lymphocytes 
(Giblett et a1 1972), with a resultant combined immune deficiency. 
A number of theories have been proposed to explain the mechanism 
of the altered lymphocyte function. Adenosine is normally 
converted to inosine by ADA in human cells (Krenitsky et al 1968). 
In the absence of ADA activity, there is an accumulation of adenine 
and deoxyadenine nucleotides (Kredi~l and Hershfield 1983) which 
inhibit DNA synthesis in the cells. The inhibition of 
s-adenosylmethionine synthesis is another cause of T-lymphocyte 
dysfunction in ADA deficiency (Kredirch and Hershfield 1983). 
ADA degrades a number of adenine analogues, including 
arabinosyl adenine, formycin and cordycepin (Agarwel et al 1975). 
These anti-metabolites have a chemotherapeutic potential which 
has been enhanced by the co-administration of deoxycoformycin, an 
inhibitor of ADA activity, in experimental animals (Johns and 
Adamson 1976). 
1.4.2. Purine nucleoside phosphorylase deficiency 
5 
Patients with a deficiency in purine nucleoside phosphorylase 
(PNP), have been described (Giblett et al 1975). They also have a 
deficiency in their T-lymphocyte function, and in contrast to the 
accumulation of adenine and deoxyadenine nucleotides in ADA 
deficiency, there is an accumulation of guanine and deoxyguanine 
nucleotides (Kredirch and Hershfield 1983). 
1.4.3. AMP deaminase deficiency 
A few cases of muscle dystrophy are due to a deficiency in 
AMP deaminase activity (Fishbein et a1 1978); an enzyme 
with a role in the purine nucleotide cycle 
(Lowenstein and Tornheim 1971). 
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1.4.4. Phosphoribosyltransferase deficiencies 
The metabolic consequences of a deficiency in HPRT activity are 
related to the extent of the intracellular enzyme deficiency (Page 
et al 1981). Purine overproduction with hyperuricaemia, gout, and 
uric acid renal stones occurs in patients with less than 50% of 
the normal activity. Whereas patients with the most marked reduction 
in HPRT activity develop the Lesch-Nyhan Syndrome (Lesch and 
Nyhan 1964), with its characteristic neurological features, 
including episodes of compulsive self-mutilation. Since the gene 
for HPRT is on the X-chromosome, these diseases are sex-linked, 
and only affect males. A deficiency in APRT activity has also 
been described (Debray et al 1976, Simmonds et al 1976). 
These patients present with renal stones consisting of 
2,8 dihydroxyadenine, which must be distinguished from 
uric acid stones for the correct diagnosis. 
1.4.5. Xanthine oxidase deficiency 
Patients with a deficiency in xanthine oxidase activity are prone 
to renal stone formation (Dent and Philpot 1954). The stones 
consist of xanthine, which is a major excretory form of purines in 
this deficiency. 
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1.4.6. PP-ribose-P synthetase overactivity 
A number of families with changes in the activity of PP-ribose-P 
synthetase have been described (Sperling et a11972, Becker et al 
1974, Zoref et al 1975). These patients have an increased rate of 
purine production de novo, and an overactivity of PP-ribose-P 
synthetase, resulting in an elavation of PP-ribose-P levels in 
their cells (Zoref et a1 1975). This is unusual since genetic 
alterations normally result in reduced activity of the affected 
enzyme. 
1.5. Gout 
Gout is the commonest clinical disorder associated with the 
metabolism of purines. It is a crystal induced arthritis, 
resulting from the deposition of monosodium urate in the synovial 
fluids of various joints (Wyngaarden and Kelley 1983). Urate is 
the end product of purine degradation in man and the primates, and 
there is a strong association between hyperuricaemia and gout. 
However, not all patients are hyperuricaemic during an attack of 
gout, and not all hyperuricaemic patients develop gout. The 
underlying changes in purine metabolism are unclear in the 
majority of patients with primary gout. There are two general 
mechanisms by which hyperuricaemia can arise: 1) a generalised 
overproduction of purines, and therefore of urate; 2) an 
underexcretion of urate by the kidneys. These two mechanisms form 
the bases for the classification of hyperuricaemia given in Table 1. 
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Table 1 
Mechanistic classification of hyperuricaemia 
1) Increased production of uric acid 
1.1 Mechanism unknown, but likely to be a consequence of 
one of the following: 
1.1.1. Increase in PP-ribose-P 
1.1.2. Increase in glutamine 
1.1.3. Defect in regulation of amidophosphoribosyl-
transferase 
1.2. Increase in nucleic acid turnover: 
e.g., tumours, infection, haemolytic anaemia, 
psoriasis 
1.3. Specific heritable enzyme defects 
e.g., HPRT deficiency, PP-ribose-P synthetase overactivity, 
glucose-6-phosphatase deficiency. 
2. Decreased excretion of uric acid: 
2.1. Specific renal tubular defect, either: 
2.1.1. Enhanced reabsorption, or 
2.1.2. Decreased secretion 
2.2 Decrease in renal functional mass 
e.g., acute or chronic renal failure 
2.3. Drugs or metabolites altering tubular secretion of 
urate 
e.g., thiazides, ethanol, salicylates (in low dosage), 
lactate, B-hydroxy-butyrate 
Table reproduced by courtesy of Prof. E. H. Harley 
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N> 
N 
+ PP. 
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1
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Fig. 2a. Reaction catalysed by HPRT with hypoxanthine as 
substrate. 
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• .. 
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Fig. 2b. Reaction catalysed by HPRT in purine metabolism in 
general. 
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2. HUMAN HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE 
Hypoxanthine-guanine phosphoribosyltransferase (HPRT, inosinate-
guanylate: pyrophosphate phosphoribosyltransferase, E.C. 2.4.2.8), 
catalyses the transfer of the 5-phosphoribosyl moiety of 
PP-ribose-P to the purine bases hypoxanthine and guanine, to form 
the nucleotides, IMP and GMP, respectively (Fig. 2). Although the 
function of the enzyme is assumed to be the salvage of the 
preformed purine bases, hypoxanthine and guanine, other roles for 
the enzyme are possible: 1) the interconversion of IMP and GMP 
(Salerno and Giacomello 1979): 2) the synthesis of PP-ribose-P 
from IMP by pyrophosphorolysis, with hypoxanthine directed towards 
excretion (Mapes and Krebs 1978). 
2.1. Localisation of HPRT 
HPRT is a cytoplasmic enzyme, with the highest activities in 
the basal ganglia of the brain (Rosenbloom et a1 1967), 
fibroblasts, lymphocytes and gonadal tissue. 
2.2. Kinetics and reaction mechanism of HPRT 
The kinetics of erythrocyte HPRT has been investigated 
extensively (Henderson et a1 1968, Krenitsky and Papaioannou 1969, 
Craft et al 1970, Giacomello and Salerno 1978). While the HPRT 
activity shows a hyperbolic relationship to the purine base 
concentration, the relationship to PP-ribose-P concentration is 
dependant on the magnesium concentration: a hyperbolic curve 
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having been obtained at high magnesium concentrations and a sigmoidal 
curve having been obtained at low magnesium concentrations (Krenitsky 
and Papaioannou 1969). A sigmoidal relationship of enzyme 
activity to PP-ribose-P concentration, regardless of the magnesium 
concentration, was reported when the enzyme was assayed below pH 
7.5 (Craft et al 1970). The dimagnesium salt of PP-ribose-P 
appears to be the true substrate for the enzyme (Salerno and 
Giacomello 1981). A sequential reaction mechanism for HPRT was 
proposed by Henderson et al (1968), on the basis of 14c-guanine 
and GMP exchange studies and on product inhibition studies. 
However, the initial velocity plots appeared to be parallel, 
and this indicated a ping-pong mechanism. They suggested 
that the ratio of the Ki to the Km for PP-ribose-P was small 
(<0.1), and that caused the initial velocity plots to have 
similar slopes. However, Krenitsky and Papaioannou determined 
that the ratio was greater than 0.1, and showed that there was an 
initial burst of IMP synthesis when the enzyme was incubated with 
hypoxanthine after it had been preincubated with PP-ribose-P and 
an excess of magnesium (Krenitsky and Papaioannou 1970). This 
indicated the existence of an enzyme-ribosylphosphate 
intermediate. They proposed two mechanisms for the HPRT reaction: 
1) at low magnesium concentrations the reaction is ordered 
sequential: 2) at high magnesium concentrations, the reaction is 
ping-pong, with PPi being released before the binding of 
hypoxanthine. Giacomello and Salerno (1978), showed that the 
magnesium complexes of IMP and PPi bind to the enzyme in a rapid 
equilibrium random fashion, while hypoxanthine and PP-ribose-P, 
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dissociate from the enzyme in an ordered sequence. Studies with 
the enzyme isolated from yeast cells, have shown that the reaction 
for the binding of purine base and PP-ribose-P is ordered, and that 
the enzyme can exist in an enzyme-phosphoribosyl form during the 
phosphoribosyltransferase reaction, but not during the 
pyrophosphorolysis reaction (Ali and Sloan 1982). The purine 
bases can therefore bind to both an enzyme-PP-ribose-P form, and 
an enzyme-phosphoribosyl form. 
2.3. Kinetic parameters of human HPRT 
The human erythrocyte HPRT has a Km value for hypoxanthine of 
9.9µM, and for PP-ribose-P of 240µM (Henderson et a1 1968, 
Krenitsky and Papaioannou 1969). The Km value for guanine is 4µM 
(Henderson et a11968, Benke et a1 1973). 
2.4. Structure of human HPRT 
The complete aminoacid sequence of human erythrocyte HPRT has been 
determined (Wilson et a1 1982). The enzyme has 217 residues 
and a molecular weight of 24 470. The NH2-terminal alanine 
is acetylated • The native enzyme may exist as a 
tetramer of identical subunits (Holden and Kelley 1978), or more 
accurately, a dimer of dimers (Holden and Kelley 1978, Johnson et 
al 1979). However, proposals that the subunit composition of the 
native enzyme is a trimer (Hughes et a1 1975, Olsen and Milman 
1977, Muensch and Yoshida 1977), or a dimer (Arnold and Kelley 
1971), have been made. 
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2.5. Electrophoresis of human HPRT 
The human erythrocyte HPRT exists in multiple electrophoretic 
forms (Arnold and Kelley 1971, Bakay and Nyhan 1972). These 
multiple forms appear to be due to post-transcriptional 
modifications of the enzyme (Kelley and Wyngaarden 1983). The 
basis of the post-transcriptional change has to be determined, but 
it may be due to phosphorylation of the enzyme or deamination of 
asparagine in the enzyme (Wilson et al 1982). 
2.6. Mutant forms of human HPRT 
The first report linking a deficiency in HPRT activity to the 
Lesch-Nyhan Syndrome was made in 1967 (Seegmiller et a1 1967), 
while later that year, a partial deficiency in the enzyme activity 
was demonstrated in a number of patients with gout (Kelley et a1 1967). 
Since then a number of reports of patients with HPRT 
activities ranging from almost undetectable to about 50% of the 
normal, have appeared. The structure of a HPRT mutant 
(HPRTLondon>' has been reported (Wilson et a1 1983). The enzyme 
was purified from the erythrocytes of a patient with a severe form 
of gout. There were reduced amounts of immunologically detectable 
enzyme in his erythrocytes (Wilson et al 1981) and in his 
transformed lymphoblasts (Wilson et a1 1982). This variant enzyme 
has previously been shown to have an abnormal Km for hypoxanthine, 
a normal isoelectric point, and smaller subunit molecular weight 
on electrophoresis (Wilson et al 1981, Wilson et al 1982). 
The mutant enzyme has an aminoacid substitution (Leu for Ser) 
at position 109. This substitution can be explained by a 
single nucleotide change in the codon for serine (UCA to UUA). 
Wilson et al (1981, 1982) were able to provide evidence for the 
existence of five structural variants of HPRT on the basis of 
changes in the size, electrophoretic, and isoelectric properties 
of variant enzyme subunits. Earlier studies demonstrated 
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that there were reduced levels of cross reactive material (CRM) in 
the majority of haemolysates prepared from patients deficient in 
HPRT activity (Upchurch et al 1975, Ghangas and Milman 1975). In the 
cases were there were normal amounts of CRM, the enzyme was shown to 
have an increased lability in the intact cells (Balis et al 1974), or 
to have an altered Km for one or more of its substrates (Gutensohn and 
Jahn 1978, Henderson et al 1976). Several HPRT variants have been 
shown to have an altered electrophoretic mobility (Bakay and Nyhan 
1972, Sweetman et al 1978, Steyn and Harley 1981, Wilson et al 1982), 
and an altered isoelectric focusing (Gutensohn and Jahn 1978, 
Wilson et al 1982). The variant HPRT activities generally 
migrate faster than normal enzyme activities during 
electrophoresis. A number of HPRT variants have an 
increased Km value for PP-ribose-P, or for the purine base 
substrates (McDonald and Kelley 1971, Benke et al 1973, Sweetman 
et a1 1978). While the variant described by Gutensohn and Jahn 
(1978) has an increase in its~ values for the purine base 
substrates, it has a reduced Km value for PP-ribose-P and a 
reduced susceptibility to the effects of active site inhibitors. 
Some variants are more susceptible to inhibition by NaF than the 
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control enzyme activity is (Benke et a11973, Sweetman et a1 1978). 
Variants with an altered susceptiblity to product inhibition 
have been described (Sperling et a1 1974, Gutensohn and Jahn 1978). 
A variant with increased heat stability has been found 
(Kelley et a11967), while a number of HPRT variants 
have shown an increased !ability on.heating (McDonald and Kelley 1971, 
Balis et a1 1974, Gutensohn and Jahn 1978). 
2.7. Molecular biology of the HPRT gene 
The gene coding for HPRT has been cloned from a mouse 
neuroblastoma cell line (Brennand et al 1982), and from a human 
DNA-library (Jolly et a1 1982). The HPRT gene is large (>32kb), 
and contains several intervening sequences. The availability of 
the cloned gene makes it possible to probe the structure of genes 
coding for HPRT variants, and will make the characterisation of 
the genetic heterogeneity of the HPRT locus, possible. 
2.8. Biochemical changes at a cellular level, associated with 
HPRT-deficiency 
Changes in a number of other enzyme activities have been described 
in HPRT deficient cells, these include an elevation in the 
activities of APRT (Kelley et al 1967, Kelley et al 1969), IMP 
dehydrogenase (Pehlke et a1 1972), some of the enzymes of the 
pyrimidine biosynthetic pathways (Beardmore et al 1973), and PP-
ribose-P synthetase (Reem 1975). Not all cells, deficient in HPRT 
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activity have elevated levels of these enzyme activities, nor has 
the mechanism of the elevation in these enzyme activities been 
determined with certainty (Kelley and Wyngaarden 1983). The 
erythrocytes and fibroblasts from patients with a deficiency in 
HPRT activity contain increased levels of PP-ribose-P (Fox and 
Kelley 1971, Greene et al 1970). This is due to a lack of 
utilisation of PP-ribose-P by HPRT. The elevation of PP-ribose-P 
in their cells may explain, in part, why these patients 
overproduce purines. While the levels of GTP are normal in 
erythrocytes from patients deficient in HPRT, the levels of the 
adenine nucleotides are reduced (Lemmen et a1 1971). The 
pyrimidine nuleotides levels are elevated levels in such cells 
(Nuki et a1 1973). 
3. ASSAY OF HPRT ACTIVITY 
A number of HPRT assays have been described, but only a few will 
be reviewed here. 
3.1. Separation of substrate and product 
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The majority of the HPRT assays use radioactive substrates and 
depend on the detection of labelled products for the determination 
of the enzyme activity. Several different methods have been used 
to separate the product and the unreacted substrate. These 
include various chromatography techniques such as ascending paper 
chromatography (Henderson et al 1968), anion exchange columns with 
DEAE-cellulose (Olsen and Milman 1978), TLC (Hatanaka et a1 1975), 
and HPLC (Ali and Sloan 1982, and Rylance et al 1982). Anion 
exchange paper (Hughes et a1 1975), or PEI-cellulose plates 
(Wohlhueter 1975), may be used to bind the product. 
Electrophoresis has also been used (Craft et a1 1970, Emmerson 
et al 1972). Most of these methods are effective in separating the 
products from the substrates, but are tedious and time consuming 
to perform, since repeated, small aliquots of the sample and cold 
carriers, have to be applied to the separation system. 
Furthermore, the recovery of the products may vary, or the 
radioactivity may be quenched, and therefore errors are possible 
in the estimation of the amount of product formed. 
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3.2. Requirements of the HPRT assay 
An assay may be required for the detection of the enzyme 
activity in post-column fractions during the purification of the 
enzyme or for the accurate measurement of the enzyme activity for 
its kinetic qharacterisation. Not all assay methods 
are suitable under these circumstances. In the first example an 
easy, rapid assay which can be adapted to a batch approach is 
needed, while in the second an accurate, sensitive, kinetic assay 
is required. The following factors were taken into consideration, 
when deciding to use a particular HPRT assay for the characterisation 
of the variant enzyme: 
1) Intitial rates had to be measured. Rate equations are 
valid for initial reaction rates, where there is a minimal change 
in substrate concentration and no accumulation of the product. 
2) The reaction had to be linear with time and enzyme 
concentration. 
3) The assay needed accuracy and precision. 
3.3. Types of HPRT assays 
Assays for HPRT can be divided into two arbitory groups: 
1) end point assays, in which the amount of product formed, 
or the amount of substrate utilised after a fixed period of time, 
is determined~ 2) kinetic assays in which the rate of appearance 
of product per unit time, is determined. 
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3.3.1. End-point assays of HPRT activity 
End-point assays are widely used, but are not ideally suited to 
the kinetic characterisation of an enzyme. The amount of product 
formed after a fixed period of time is an integrated value, and 
there is no indication whether the rate of production of the 
product is constant throughout the assay. A latent period for 
instance, will not be detected. Inadequate separation of the 
product and substrate may be difficult to detect. Although these 
problems can be minimised, they may cause uncertainty in 
individual assays. In an attempt to minimise these problems, it 
has been suggested that the ratio of product to substrate be 
determined (Olsen and Milman 1978). However, this approach 
assumes that the product and substrate are recovered at the same 
efficiency, and that the separation of the two is complete. An 
alternative method is to measure the amount of hypoxanthine 
used by the enzyme in one hour (Johnson et al 1977). 
The enzyme and IMP are precipitated with Lac13 , and the change in 
extinction at 249nm due to the reduction in hypoxanthine 
concentration is measured. This assay is useful for screening 
samples for HPRT activity, and it was used to detect HPRT activity 
in the post-column fractions obtained during the partial 
purification of the variant enzyme. 
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3.3.2. Kinetic assays of HPRT activity 
Giacomello and Salerno (1977), have described a method for linking 
the rate of formation of GMP by HPRT activity to the oxidation of 
NADH, and of measuring the rate of change in extinction at 340nm. 
This assay is convenient and quick to perform. However, when used 
to determine the HPRT activity in dialysed haemolysates the 
relationship between the enzyme activity and the increase in protein 
concentration was not linear. The guanosine-5'-monophosphate 
kinase, used in the marker enzyme system, was unstable and 
expensive. However, the initial kinetic characterisation of the 
variant HPRT, and the studies on the partialy purified variant 
HPRT, were performed with this assay. A kinetic assay, described 
by Wohlhueter (1975), was modified and used in the kinetic 
characterisation of the variant enzyme. The assay was performed 
as follows: aliquots of the assay mixture were taken at minute 
intervals, and the amount of product formed at each point, was 
measured. The data wel't fitted to the equation for a straight 
line and the rate of formation of the product was determined from 
the slope of the line. Non-separation of the product and the substrate 
was indicated by the value of the intercept on the ordinate. A latent 
period, instability of the enzyme activity or depletion of the 
sustrates would have been detected as non-linearity in the rate of 
product formation. This assay was also used in the double 
inhibition studies performed to elucidate the mechanism of 
substrate inhibition found in the variant enzyme. This assay is 
referred to as the 'multiple end-point assay'. 
The details of the various HPRT assays are described in the 
relevant sections, under 'Methods'. 
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SECTION 1 
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4. KINETIC CHARACTERISATION OF THE VARIANT HPRT 
4.1. Materials 
The radioactive substrates [a-14c]-Hypoxanthine (used at 20.15 
dpm/pmol), and [a-14c]-Guanine (114dpm/pmol), were obtained from 
Amersham and New England Nuclear, respectively. They were checked 
for purity by TLC and were found to be 96% and 93% pure, 
respectively. Hypoxanthine, guanine, PP-ribose-P (sodium salt), 
and IMP were obtained from Sigma, and tetra-sodium pyrophosphate, 
from B.D.H. The PP-ribose-P was quantitated by assaying the 
HPRT activity in the presence of a limiting amount of PP-ribose-P, 
and an excess of hypoxanthine. The actual PP-ribose-P 
concentration was determined from the amount of product formed 
when the reaction had run to completion. When assayed in this 
manner the PP-ribose-P was found to be 94% pure. All other 
reagents were of analytical grade. 
4.2. Enzyme extracts 
The enzyme extracts were prepared from 10ml of fresh, heparinised 
blood from T.K. and from a normal control. The plasma and buffy coat 
• was removed after centifugation at 1 OOOg for 10 minutes in an 
MSE desk top centrifuge. The red cells were washed twice with 
normal saline, and were lysed by adding 4 volumes of cold, 
distilled water~ the stroma was removed by centrifugation. 
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The haemolysates were dialysed for 16 hours at 4°C against two 
changes of 5 litres of 50mM tris-HCl, pH 7.8, containing lmM 
dithiothreitol. The dialysed lysate was frozen in aliquots of 
500µ1, and stored at -20°C. After 4 weeks of storage there was a 
10% loss in enzyme activity, compared with a loss of over 50% in 
samples stored for 2 days at 4°C. The thawed lysates were diluted 
immediately before use to give 100-200µU of enzyme activity per 
20µ1 aliquot. The protein was determined by a modification of the 
method of Lowry et al (1951). 
4.3. Methods 
4.3.1. Enzyme assay 
The HPRT activity was assayed by a modification of the method of 
Wohlhueter (1975). All assays were performed at 37°C. Each assay 
contained the following in a final volume of 100µ1: 50mM 
tris-HCl, pH 7.8, 14mM MgC1 2 , PP-ribose-P and 
14c-hypoxanthine or 
14c-guanine at the appropriate concentrations. Assay tubes were 
brought to 37°C for one minute before the reaction, which was 
started by adding 20µ1 of the enzyme preparation. Four aliquots 
of 20µ1 were taken at one minute intervals, and applied to PEI-
cellulose plates (Merck), which were pre-heated to 70°C on a heating 
block. The PEI-cellulose plates were pre-ruled into 2.5x2.5cm squares, 
one for each aliquot. In this way twelve assays could be 
accommodated on each plate. The plates were washed by placing 
them in a chromatography tank containing 4 litres of tap water for 
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5 minutes. The plates were removed before the water was changed. 
Four of these washes were required for assays using hypoxanthine as 
the substrate, and six for those with guanine as the substrate. 
Up to four plates were washed at a time. After the plates had 
dried, the PEI-cellulose was scraped off the plates, and the 
PEI-bound nucleotide added to 6ml of Instagel (Packard), the 
radioactivity was counted in a Beckman LS-250 scintillation counter. 
DE81 paper (Whatman) was used as an alternative anion exchanger to 
PEI-cellulose in a number of assays. The paper was pre-treated 
with 20mM EDTA, pH 8.0, pre-ruled into 2.5x2.5cm squares, and cut 
into strips of 2x4 squares. The unreacted substrate was washed 
off the paper by suspending the strips in a 51 beaker, and by 
allowing tap water to flow through it at a rate of 1 1/minute for 
45-60 minutes. The strips were washed with ethanol in order to 
decrease their fragility. The individual squares were cut out and 
assayed for radioactivity in 10ml of Instagel. Less than 1% of 
the unreacted substrate remained on the paper, while less than 10% 
of the product was lost. Quenching of radioactivity by the 
PEI-cellulose and the paper was 10%. All these factors were taken 
into consideration when the enzyme activity was calculated. The 
data was analysed by linear regression, on a Tektronix 4050 
computer, by the method of least squares (Bevington 1969). The 
reaction was regarded as linear when a correlation of greater than 
0.99 was obtained. All the assays were performed in duplicate, and 
the activities given are the mean of 1-3 sets of assays. The 
magnesium concentration was kept constant at 14mM, which was ten 
times greater than the highest PP-ribose-P concentration used 
(Giacomello and Salerno 1978). The unit of enzyme activity (U), 
was defined as that which catalysed the formation of one micromole 
of product per minute. 
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4.3.2. Data analysis 
The values for the various kinetic parameters of the control and 
variant enzyme, were obtained by the reiterative method of Wilkinson 
(1961) by fitting the data directly to the appropriate rate equations. 
Reciprocal velocities were ploted graphically against the 
reciprocals of the substrate or inhibitor concentrations. These 
curves were used to obtain estimates of the kinetic parameters, 
which are required in the reiterative method. The figures show 
curves with the best fit to the data. The data obtained for the 
curves following hyperbolic kinetics were fitted to equation 1, 
those for substrate inhibition were fitted to equation 2, and 
those for double inhibition were fitted to equation 3. 
v= VA x (K+A)-l ( 1) 
( 2) 
( 3) 
In equation 3, I and J are inhibitors of the enzyme activity, Ki 
and Kj are the dissociation constants for I and J, v0 is the 
enzyme activity in the absence of of the inhibitors, and Bis the 
interaction constant for the inhibitors on the enzyme. In the 
other equations, K is the Michaelis constant or the apparent 
Michaelis constant, Vis the maximum velocity and Ki is the 
dissociation constant for the second substrate molecule. 
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Fig. l· Linearity of the variant HPRT activity versus time and 
protein concentration. Enzyme activity was determined at 350µM 
hypoxanthine or 20µM guanine, and l.4mM PP-ribose-P. A) The 
amount of IMP formed was determined from aliquots of 20µ1 taken 
from the assay mixture at 4 minute intervals. The total assay 
volume was 200µ1 and the reaction was started with 40µ1 of 
enzyme extract. B) Hypoxanthine as substrate: enzyme activity 
was determined in aliquots of enzyme activity containing 0.22 to 
0.88 and 0.08 and 0.16 mg protein for the variant and control, 
respectively. C) Guanine as substrate: enzyme activity was 
determined in aliquots of enzyme activity containing 0.3 to .0.6 
and 0.04 to 0.08 mg protein for the variant and control, 
respectively. All other conditions were as described under 
'Methods'. ( • ), control: ( + ), variant. 
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4.4. Results 
The time dependence of formation of the product, IMP, in the assay 
of the variant HPRT is shown in Fig. 3a. The rate of formation of 
IMP was constant for 30 minutes. The initial hypoxanthine 
concentration was 350µM, of which 34% was converted to product 
within 30 minutes. The formation of IMP by the control enzyme was 
also constant over this period. In Fig. 3b, the effect of protein 
concentration on the variant enzyme activity is shown. Both 
control and variant enzyme activities increased linearly with an 
increase in the protein concentration. At the substrate 
concentration used, the control enzyme preparation 
contained 4 times the activity of the variant enzyme preparation. 
Similarly, the activities of the variant and control enzymes were 
linear when plotted against protein concentration with guanine as 
the purine base substrate (Fig. 3c). 
4.4.1. Comparison of the variant and control enzyme activities 
4.4.1.1. Hypoxanthine as the varied substrate. 
The activities of variant and control HPRT, assayed at a constant 
PP-ribose-P concentration and at varied hypoxanthine 
concentrations are shown in Fig. 4a. The control enzyme activity 
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demonstrated a hyperbolic dependence on the hypoxanthine 
concentration, while the variant enzyme activity reached its 
greatest activity at 70µM of hypoxanthine. Thereafter it showed a 
progressive decrease as the hypoxanthine concentration was 
increased. At 350µM of hypoxanthine the variant activity was 
approximately 50% of the maximal activity obtained. The double 
reciprocal plots of the enzyme activities versus hypoxanthine 
concentration, demonstrated that the control enzyme activity 
followed Michaelis-Menten kinetics, while the variant followed 
those for substrate inhibition. The data were fitted to the 
appropriate rate equations, and the values for the various kinetic 
parameters were obtained (Table 2). The values for the Km(app) 
are 10+ 2µM and 34+ 16µM for the control and variant enzyme 
activities, respectively, while those for the Vmax(app) are 
1779+ 39µU/mg prot., and 1937+ 427µU/mg prot., respectively. The 
variant enzyme has a Ki(app) for hypoxanthine of 118+ 28µM. 
4.4.1.2. Guanine as the varied substrate. 
The variant enzyme also demonstrated substrate inhibition with 
guanine as the purine substrate (Fig. 4b). The enzyme activity 
reached a maximum value at a guanine concentration of 6µM, with 
about 70% of the activity remaining at 25µM of guanine. The 
values for the Km(app)' Vmax(app)' and Ki(app)' are 2.6µM, 
1179+ 295µU/mg prot., and 28~ 9µM, respectively (Table 2). The 
control enzyme activity showed a hyperbolic relationship to the 
guanine concentration, and the values obtained for the Km(app)' 
and Vmax(app) are 3+ 0.6µM and 1298+ 72µU/mg prot., respectively. 
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conditions were as described under 'Methods'. 
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4.4.1.3. PP-ribose-P as the varied substrate. 
The variant and control enzyme activities were determined at a 
fixed hypoxanthine concentration of 350µM, with PP-ribose-P as the 
varied substrate (Fig. 4c). No substrate inhibition by PP-ribose-P 
could be demonstrated for the variant enzyme. The low activity of 
the variant was due to inhibition by hypoxanthine, which was held 
at the relatively high concentration of 350µM to avoid any 
significant change in the base concentration during the assay. 
The data were fitted to equation 1, and values were obtained for 
the Km(app)' and Vmax(app)• The respective values for the variant 
enzyme are 244~ 54µM and 180~ 20µU/mg prot.,and those for the 
control enzyme activity, are 251+ 54µM and 1399+ llOµU/mg protein 
(Table 2). 
4.4.2. Determination of the true Km, true Vmax' and true Ki 
of the variant enzyme activity for hypoxanthine 
The values for the 1 true 1 kinetic parameters of the variant 
enzyme were obtained by assaying the enzyme activity with PP-ribose-P 
as the variable substrate, at different, fixed concentrations 
of hypoxanthine (Fig. Sa). By fitting the data to 
equation 1, values for the Vmax(app) at each hypoxanthine 
concentration, could be obtained. These values were fitted to 
equation 2, and the values for the true Km, true V , and true K· max i 
for hypoxanthine, were obtained. This is illustrated in Fig. Sb, 
where the reciprocal of the Vmax(app) value for PP-ribose-P is 
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plotted against the reciprocal of the hypoxanthine concentration. 
A curve typical of substrate inhibition by hypoxanthine was 
obtained. The values for the true Km, true Vmax and true Ki, are 
26+ µM, 1761+ 382µU/mg prot., and 80+ 20µM, respectively {Table 2). 
4.4.3. Determination of the true Km, true Vmax' and true Ki 
of the variant enzyme for guanine 
The values for the true Km, true Vmax' and true Ki for guanine 
were obtained as described for hypoxanthine. The double 
reciprocal plots of enzyme activity versus PP-ribose-P 
concentration are shown in Fig. 6a. The values for the Vmax{app) 
for PP-ribose-P, obtained at each guanine concentration were 
fitted to equation 2, and the values for the true Km, true Vmax 
and true Ki, were obtained {Fig 6b). They are l.87~0.9µM, 
1152+ 219µU/mg prot., and 27.5+ 8.9µM, respectively {Table 2). 
4.4.4. Determination of the true Km and true Vmax of the variant 
enzyme for PP-ribose-P 
The variant enzyme activity was assayed at a number of fixed 
concentrations of PP-ribose-P with hypoxanthine as the variable 
substrate {Fig 7), and the data was fitted to equation 2, in order that 
the values for the Vmax{app) for hypoxanthine could be obtained. 
These values were fitted to equation 1 {Fig. 7, inset), and the values 
for the true Km and true Vmax for PP-ribose-P were obtained. These 
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Fig. Sa. Variant HPRT activity at different fixed concentrations 
of hypoxanthine and varying PP-ribose-P concentration. The 
hypoxanthine concentrations were: ( •), 18µM: ( y ), 45µM: 
( • ), 120µM: ( • ), 180µM: ( • ), 300µM. 
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Fig~ Sb. Replo~ of the values for Vmax(app) for PP-r~bose-P 
against the reciprocal of the hypoxanthin~ concentration. The 
value for the Vmax(a ) for PP-ribose-P at each hypoxanthine 
concentration was ob~~ined by fitting the data shown in Fig. Sa, 
to equation 1. 
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Fig. Sc. Replot of the slopes of the double reciprocal plots 
of the""variant enzyme activity and PP-ribose-P concentration 
against the reciprocal of the hypoxanthine concentration. The 
slopes were calculated from the values for Vmax(app) and Km(app)• 
obtained by fitting the data shown in Fig. Sa, to ~quation I. 
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Fig. 6b. The replot of the values for Vmax(a ) for PP-ribose-P 
agalnst the reciprocal of the guanine concent~ftion. The value 
for the Vmax(app) for PP-ribose-P at each guanine concentration 
was obtained ~y fitting the data shown in Fig. 6a to equation 1. 
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Fig. 2· Variant HPRT activity at different fixed concentrations 
of PP-ribose-P and varying hypoxanthine concentrations. The PP-
ribose-P concentrations were: ( +), lOOµM; ( • ), 200µM; 
( • ), 300µM; ( ~ ), 400µM; ( ~ ), 600µM. All other conditions 
were as described under 'Methods'. The figures opposite the 
curves indicate the PP-ribose-P concentration (µM). The inset 
shows th7 reciprocal of th~ Vmax(app) versus the reciprocal of the PP-ribose-P concentration. 
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Fig.~- Variant HPRT activity at different fixed concentrations 
of PP-ribose-P and varying guanine concentrations. The PP-
ribose-P concentrations were: ( 0 ), lOOµM: ( • ), 200µM: 
( V ) , 3 0 0 µ M : ( • ) , 4 0 0 µ M : ( ~ ) , 6 0 0 µ M : ( D ), 10 0 0 µ M • Al 1 
other conditions were as described under 'Methods'. The figures 
opposite the curves indicate the PP-ribose-P concentration (µM). 
The inset shows the reciprocal of the Vm~x(app) versus the 
reciprocal of the PP-ribose-P concentration. 
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Table 2 
The kinetic parameters obtained for the variant and control HPRT 
activities, assayed by the kinetic assay of Wohlhueter (1975). 
A) Hypoxanthine as the purine substrate 
Km(app) 
µM 
vmax(app) 
µU/mg.prot 
Ki(app) 
µM 
Km(true) 
µM 
Vmax(true) 
µU/mg.prot 
Ki(true) 
N.D.= not determined 
Hypoxanthine 
Variant Control 
34+ 16 10+ 2 
1937+ 427 1779+ 39 
118+ 28 
26+ 10 N.D. 
1761+ 382 N.D. 
80+ 20 
PP-ribose-P 
variant Control 
244+ 75 251+ 54 
180+ 20 1399+ 110 
227+ 116 N.D. 
1779+ 371 N.D. 
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Table 2 
The kinetic parameters obtained for the variant and control HPRT 
activities, assayed by the kinetic assay of Wohlhueter (1975). 
B) Guanine as the purine substrate 
Km(app) 
µM 
vmax(app) 
µU/mg.prot 
Ki(app) 
µM 
Km(true) 
µM 
Vmax(true) 
µU/mg.prot 
Ki(true) 
µM 
N.D.= not determined 
Guanine 
variant Control 
2.6+ 1. 3 3. 0+ 0. 6 
1179+ 295 1298+ 72 
28+ 9 
1.9+ 0.9 N.D. 
1152+ 219 N.D. 
27.5+ 8.9 
PP-ribose-P 
Variant Control 
N.D. N.D. 
N.D. N.D. 
271+ 22 N.D. 
1108+ 35 N.D. 
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are 227+ 116µM and 1779~ 37lµU/mg prot., respectively (Table 2). 
The true Vmax and true Km for PP-ribose-P with guanine as the 
purine substrate were obtained, as is illustrated in Fig 8. The 
values for the true Vmax and true Km are 1108+ 35µU/mg prot., and 
271+ 22µM, respectively (Table 2). 
4.4.5. Investigation of the mechanism of substrate inhibition of 
the variant HPRT activity 
The inhibition of the variant HPRT activity is shown as a plot of 
the reciprocal of enzyme activity versus the concentration of 
hypoxanthine (Fig. 4a, inset). The inhibition of enzyme activity 
was proportional to the hypoxanthine concentration above lOOµM. 
This pattern of inhibition has been termed linear or total 
substrate inhibition (Cleland 1979, Uhr et a1, 1974). Further 
information about the nature of the substrate inhibition can be 
obtained from the curves shown in Fig. Sa, where the reciprocals 
of enzyme activity, assayed at different fixed concentrations of 
the inhibitory substrate, hypoxanthine, were plotted against the 
reciprocals of the non-inhibitory substrate, PP-ribose-P. The 
slopes of the curves decreased with increasing hypoxanthine 
concentration, whereas their intercepts on the ordinate increased 
after showing an initial decrease in value. A replot of the 
slopes versus the reciprocals of the hypoxanthine concentrations, 
showed a linear relationship (Fig. 5c), while the intercept replot 
gave a curve typical of substrate inhibition by hypoxanthine (Fig. Sb). 
This pattern of inhibition has been termed uncompetitive 
substrate inhibition (Cleland 1979, Uhr et a1, 1974), and is 
characteristic of an ordered sequential reaction mechanism, where 
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the non-inhibitory substrate binds before the inhibitory substrate 
i.e. PP-ribose-P binds before hypoxanthine. Two mechanisms have 
been proposed to explain uncompetitive substrate inhibition 
(Cleland 1979, Northop and Cleland 1974). Firstly, the inhibitory 
substrate may bind to the central complexes formed during the 
reaction and inhibit catalysis or product release. Secondly, the 
inhibitory substrate may interact with an enzyme-product 
intermediate and prevent the release of the product from the 
enzyme. Double inhibition experiments may be used to distinguish 
between these possibilities (Cleland 1979, Northop and Cleland 
1974). In the particular case of the variant HPRT, hypoxanthine 
could interact with the central complexes, 
enzyme-hypoxanthine-PP-ribose-P or enzyme-IMP-PPi• Alternatively 
hypoxanthine could interact with an enzyme-PPi intermediate to 
give a dead-end complex. Double inhibition assays of the variant 
enzyme were performed at hypoxanthine concentrations of between 
150 and 350µM. These concentrations of hypoxanthine are well 
above the Ki of 80~ 20µM. When the product PPi was used as a 
second inhibitor, plots of the reciprocals of enzyme activities 
versus inhibitory substrate concentration showed a series of 
straight lines, the slopes of which increased with increasing 
concentrations of PPi (Fig. 9a). The data were fitted to equation 3, 
and a value for B of 0.69 was obtained. Bis the interaction constant 
of the inhibitors~ the product PPi and the substrate hypoxanthine. 
A value for B of unity is expected if the two inhibitors 
acted independently. Higher values indicate repulsive 
interaction. The actual value obtained for B, indicates positive 
interactions between PPi and hypoxanthine (Northop and Cleland 1974, 
Yonetani and Theorell 1964), resulting in observed inhibition higher 
than that expected by simple summation. 
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Fig. 9a. Double inhibition of variant HPRT activity by 
hypoxanthine and pyrophosphate. Enzyme activity was determined 
at hypoxanthine concentrations well above the Ki for hypoxanthine 
and at different fixed concentrations of pyrophosphate. The 
pyrophosphate concentrations were: ( • ), nil; ( • ), O.SmM; 
( •), lmM. The PP-ribose-P concentration was l.4mM. All other 
conditions were as described under 'Methods'. 
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Fig. 9b. Double inhibition of va
riant HPRT activity by 
hypoxanthine and IMP. Enzyme ac
tivity was determined at 
hypoxanthine concentrations well
 above the Ki for hypoxanthine 
and at different fixed concentra
tions of IMP. The IMP 
concentrations were: ( • ), nil; ( T )
, SOµM; ( • ), lOOµM; 
( • ), 200µM. The PP-ribose-P concentr
ation was l.4mM. All 
other conditions were as describ
ed under 'Methods'. 
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Fig. 10. The proposed reaction mechanism for the variant HPRT at 
high concentrations of hypoxanthine. 
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When IMP was used as the second inhibitor, a series of almost parallel 
lines was obtained (Fig. 9b). The value of Bin this case was 
greater than 6, showing that IMP and hypoxanthine interacted 
repulsively, which is to be expected if they bound at the same 
site. Thus the double inhibition experiments demonstrate that the 
inhibitory substrate, hypoxanthine binds to an enzyme-PPi 
intermediate to form an enzyme-hypoxanthine-PPi complex, which is 
responsible for the loss of enzyme activity at high hypoxanthine 
concentrations (Fig. 10). 
4.5. Discussion 
The values of the Km(app) and Vmax(app) obtained for both the 
variant and control HPRT activities with each of thesubstrates.are 
similar (Table 2). These values, and those obtained for the true 
Km, true Vmax of the variant enzyme, are in close agreement with 
those published for human erythrocyte HPRT (Henderson et al 1968, 
Krenitsky and Papaioannou 1968, Benke et a1 1973). Thus the low 
activity obtained for the variant at high purine base 
concentration, unlike many of the previously described low 
activity variants, was not due to changes in the kinetic 
parameters, or to any methodological factors which would influence 
the activity of the control enzyme as well. Instead, the low 
activity was caused by total substrate inhibition (Cleland 1979) 
of the enzyme activity by the purine base substrates (Fig. 4a, 
inset). The kinetics of the enzyme activity and its dependence on 
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the concentration of PP-ribose-P at different fixed concentrations 
of hypoxanthine (Fig. Sa, b, c}, is compatible with uncompetitive 
substrate inhibition and is associated with an ordered sequential 
reaction mechanism (Cleland 1979). The positive interaction 
between the inhibitory substrate hypoxanthine, and PPi, inferred 
from a B value of less than one, is compatible with hypoxanthine 
interacting with an enzyme-PPi intermediate. A proposed reaction 
mechanism for the variant HPRT is represented diagramatically in 
Fig. 10. The binding of the substrates is ordered sequential, 
with PP-ribose-P binding before hypoxanthine. After the release 
of IMP, hypoxanthine binds to the enzyme pyrophosphate 
intermediate. Pyrophosphate is unable to dissociate from this 
complex and a dead-end complex is formed. The plot of the 
reciprocal activity versus hypoxanthine concentration (Fig. 4a, 
inset} is characteristic of that associated with the formation of 
a dead-end complex (Cleland 1979). In the case of the normal 
enzyme, hypoxanthine is unable to bind to the enzyme-pyrophosphate 
intermediate. A random, sequential release of products as 
proposed for the normal enzyme by Giacomello and Salerno (1978), 
would not preclude this mechanism of inhibition, as an enzyme 
pyrophosphate intermediate would still be formed. It is 
interesting to note that the binding of the substrates to the 
variant enzyme is ordered sequential at ratios of magnesium to 
PP-ribose-P of greater than five to one, at which the normal 
enzyme has been reported to have a ping-pong mechanism (Krenitsky 
and Papaioannou 1968). Substrate inhibition has not been reported 
as a cause of decreased activity in assays for HPRT, nor, to my 
knowledge, hac 3ubstrate inhibition been associated with a 
decrease in enzyme activity in any other metabolic disorder. 
There are several possible mechanisms for the aquisition of 
substrate inhibition in the variant enzyme: 
1) a mutation in the coding sequence, or defective post-
translational modification of the mRNA, for the enzyme; 
2) altered post-translational modification of the enzyme; 
3) deficiency or absence of an effector molecule required 
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for normal HPRT activity. The molecular defect in HPRTLondon has 
been defined as an amino acid substitution (serine-to-leucine) in 
position 109 (Wilson et a11983). Wilson et al (1982), using 
isoelectric focusing, have shown differences in 
post-translational modification of HPRT from red blood cells and 
from lymphoblasts in a number of different patients. Hora et al 
(1982) have presented evidence of a non sex-linked HPRT 
deficiency, which implies a defect separate from the HPRT gene on 
the X-chromosome. Wohlhueter (1975), has demonstrated different 
kinetics for HPRT in post-microsomal supernatants from rat livers 
and hepatoma cell cultures. It is interesting to note that the 
rat liver enzyme appeared to show substrate inhibition by 
hypoxanthine. Cultured cells from the patient T.K. showed 
approximately 10% of the relative incorporation of 14c-labelled purine 
substrates to 3H-thymidine into acid precipitable material, as 
compared to control cell lines (11.5). This indicates a deficient 
intracellular activity of the variant HPRT. Whether this reflects 
intracellular behavior similar to that observed in vitro, is not 
known, but if this is the case, these results imply an 
intracellular hypoxanthine concentration of greater than 300µM 
at the vicinity of the active site. 
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Detailed protein structural studies will be required to define 
the molecular basis of the substrate inhibition observed in vitro, 
therefore the term 'variant enzyme 'has been used throughout as an 
operational definition. 
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5. THE CONTINUOUS SPECTROPHOTOMETRIC ASSAY OF HPRT ACTIVITY 
5.1. Materials 
The enzymes, pyruvate kinase (200U/mg, 2mg/ml), lactate 
dehydrogenase (300U/mg, 5mg/ml), and guanosine-5'-monophosphate 
kinase (lOU/mg, 2mg/ml), as well as GMP and NADH, were obtained 
from Boehringer Mannheim, while ATP, guanine, phosphoenolpyruvate 
and PP-ribose-P (sodium salt) were obtained from Sigma. All 
other chemicals were of analytical grade. 
5.2. Enzyme extracts 
The enzyme extracts used in this assay were prepared in a 
similar manner to those used in the multiple end point assay. 
Alternatively, the partially purified variant HPRT activity was used. 
5.3. Methods 
In this assay the HPRT activity is linked via a marker enzyme 
system to the oxidation of NADH. (Giacomello and Salerno 1977). 
The GMP that is formed by the activity of HPRT, is converted to 
GDP by the action of guanosine-5'-monophosphate kinase, with ATP 
as co-substrate. The GDP is phosphorylated to form GTP, and 
the ATP regenerated by the activity of pyruvate kinase on the 
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dinucleotides and on phosphoenolpyruvate. This reaction also 
results in the formation of pyruvate, which is reduced to lactate 
by the lactate dehydrogenase activity, with the oxidation of NADH 
to NAD+, the rate of which can be monitored at 340nm. Both the 
GDP and ADP act as substrates for pyruvate kinase, therefore the 
NADH is oxidised stoichiometricaly at a ratio of 2:1 for each 
mole of GMP that is formed. The assays were performed at 37°C, 
and each assay contained the following in a final volume of 1ml: 
50mM tris-HCl, pH 7.5, 40mM MgS04 , l.4mM PP-ribose-P, 130mM KCl, 
160µM NADH, 2U of pyruvate kinase activity, O.lU of guanosine-5 1 -
monophosphate kinase activity, 7.5U of lactate dehydrogenase 
activity, 10µ1 of the enzyme extract. The assay mixture was 
brought to 37°C for 5 minutes in the cuvette chamber before the 
reaction was started by adding guanine at the appropriate 
concentration. There was a lag period of approximately 
2 minutes before the reaction became linear. When dialysed 
haemolysates were used as the source of the enzyme activity, the 
reaction was monitored in a Varian Techtron Model 635 
spectrophotometer with a Corning Recorder 840, whereas when the 
partialy purified enzyme activity was assayed, a Beckman DU-2 
spectrophotometer interfaced with a Data General Micronova 
computer, was used. Both these systems gave similar results, 
With the first, however, the results were calculated from the 
tracing of the change in extinction, whereas with the second the 
change in extinction was obtained directly. The data were fitted to 
the appropriate rate equations as was described for the multiple end 
point assay. 
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Fig . .!l.· Continuous spectrophotometric assay: activity of the 
variant HPRT versus protein concentration. A) Variant HPRT 
activity in samples of dialysed haemolysate, containing 0.1 to 
0.65 mg protein per assay. B) Variant HPRT activity in samples 
of the partially purified protein, containing 0.03 to 0.16 mg 
protein per assay. 
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5.4. Results 
5.4.1. Haemolysates 
The continuous spectrophotometric assay (Giacomello and Salerno 
1977), was used in the initial characterisation of the variant 
HPRT activity. The enzyme activity in dialysed haemolysates was 
not linear with protein concentration (Fig. lla), while a linear 
relationship was obtained when the enzyme activity was partialy 
purified (Fig. llb). The low activity obtained in haemolysates 
with this assay, led to the assumption that the Vmax(app) for the 
variant enzyme with guanine as the purine base substrate, was 
lower than that of the control enzyme. However, the protein 
content per assay was twice that in the control enzyme activity 
assays, a factor that could explain the discrepancy in the Vmax 
values. The kinetic parameters for the control and variant enzyme 
activities, are compared in Table 3. The values for the Km(app) 
for the control and variant activities are in close agreement with 
each other, 2.0µM and l.7µM, respectively. These values are 
similar to those obtained with the multiple end point kinetic 
assay, 3.0µM and 2.6µM, respectively (Table 2). A value of 68µM 
was obtained for the Ki(app) for guanine, when the variant enzyme 
activity was assayed by the continuous spectrophotometric assay, 
and 28µM, when the multiple end-point assay was used. 
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Table 3 
Kinetic parameters obtained for the variant and control HPRT 
activities, assayed by the continuous spectrophotometric assay 
(Giacomello and Salerno 1977) 
Enzyme activity 
Variant 
Control 
Vmax(app) 
µU/mg.prot 
229+ 26 
2104+ 46 
Km(app) 
µM 
1.7+ o.s 
2.0+ 0.2 
Ki(app) 
µM 
68+ 16 
5.4.2. Discussion 
Similar values for the kinetic parameters of the variant and 
control HPRT activities for guanine were obtained by the 
continuous specrophotometric assay and the multiple end-point 
assay of Wohlhueter (1975), (Tables 2 & 3). Therefore the 
results obtained with the multiple end-point assay, were 
reproducible using a second method, and were accepted with a 
greater amount of certainty. 
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5.4.3. Effect of partial purification of the variant enzyme on the 
degree of substrate inhibition obtained with guanine 
The degree of substrate inhibition of the variant enzyme activity, 
was determined from the percentage loss in activity at 120µM 
guanine compared with that at 20µM guanine. For the partialy 
purified activity it varied between 12% and 28%, while values of 
25% and 33% were obtained for the activity in haemolysates. These 
findings show that the degree of inhibition in both enzyme 
preparations was similar. The enzyme activity in haemolysates was 
more stable than that in the partially purified form and could be 
used for the further characterisation of the variant enzyme. 
Similarly the results obtained by Henderson et al (1968), with the 
HPRT activity in dialysed haemolysates, were similar to those 
obtained by Krenitsky and Papaioannou (1968), with a partially 
purifed HPRT preparation. 
59 
6. THE£!! DEPENDENCE OF HPRT ACTIVITY 
6.1. Methods 
The pH dependence of the variant and control HPRT activities, was 
determined for pH ranging from pH 7.2 to pH 10. The buffer used 
was tris-HCl (25rnM),· and glycine (25rnM), at the appropriate pH. 
The magnesium concentration was kept constant at 5rnM, and 
the PP-ribose-P concentration was l.4rnM. The purine base 
substrate was 14c-hypoxanthine (350µM, 5.5 dpm/pmol), in a 
final assay volume of 100µ1. The reaction was started by adding 
20µ1 of enzyme extract and the amount of 14c-IMP formed after 4 
minutes was determined. An aliquot of 20µ1 of the reaction 
mixture was placed on DE81 paper, the unreacted hypoxanthine 
removed by washing with tap water and the radioactivity, remaining 
on the paper, was measured. 
6.2 Results and Discussion 
Both enzyme activities had a broad pH optimum (Fig. 12). The 
maximal activity for the variant enzyme was found between a pH of 
8.4 and 9.2, while that for the control enzyme was between pH 8.4 
and pH 10. Because of the low enzyme activity below pH 7.5, the 
enzyme assays were performed at pH 7.8 in the kinetic studies on 
the variant HPRT. A similar, broad pH optimum for erythrocyte HPRT 
activity has been reported (Krenitsky et al 1968). 
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Fig. 12. The pH dependence of the variant and control HPRT 
activities. Enzyme activity was determined in a tris-glycine 
buffer at the appropriate pH, as has been described under 
'Methods'. ( •) control, ( ~) variant. 
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7. MAGNESIUM DEPENDENCE OF HPRT ACTIVITY 
7.1. Methods 
The effect of the magnesium concentration, at a constant 
concentration of PP-ribose-P, on the variant and control enzyme 
activities, was measured by an end point assay. The assay mixture 
contained the following in a final volume of 100µ1: 50mM 
tris-HCl, pH 7.8, lmM PP-ribose-P, 350µM 14c-hypoxanthine 
(5.5 dpm/pmol), and Mgso4 at the appropriate concentration. The 
reaction was started with 20µ1 of enzyme extract and the amount of 
IMP formed after 4 minutes, was determined. The curve of enzyme 
activity versus magnesium concentration was normalised by dividing 
the enzyme activity at each magnesium concentration by the 
activity at the optimal magnesium concentration. 
7.2. Results and Discussion 
The curves obtained for the variant and control enzyme activities 
were similar, the maximal activity occurring at magnesium 
concentrations of between 25-lOOmM (Fig. 13). Dimagnesium 
PP-ribose-P is the true substrate for the enzyme (Salerno and 
Giacomello 1981). The HPRT assays, used in the characterisation of 
the variant enzyme, were performed at magnesium concentrations of 
10-20 times higher than the PP-ribose-P concentrations. 
The inhibition of enzyme activity at magnesium concentrations 
of greater than lOOmM is thought to be due to the competition 
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of free magnesium ions with dimagnesium PP-ribose-P for binding sites 
on the enzyme (Salerno and Giacomello 1981). 
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Fig • .!1_. Effect of magnesium concentration on the variant and 
control HPRT activity. The enzyme activities were determined at 
a fixed concentration of PP-ribose-P of lmM, and MgSOi 
concentrations of between 1 to 200mM. All other conditions were 
as described under 'Methods'. ( •) control, ( •) variant. 
8. EFFECT OF MIXING HAEMOLYSATES ON HPRT ACTIVITY 
8.1. Methods 
Haemolysates obtained from the patient T.K. and from a normal 
individual were diluted with SOmM tris-HCI, pH 7.8, to give 
approximately 200µU of HPRT activity at 300µM hypoxanthine, per 
20µ1 of haemolysate. Equal aliquots of each haemolysate were 
mixed and preincubated on ice for 30 minutes and the HPRT 
activity was assayed. 
8.2. Results and Discussion 
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The HPRT activity _predicted in the mixture of haemolysates was 
396µU/mg prot., and values of 383 and 405µU/mg prot. were obtained 
(Table 4) • This demonstrated that there was no inhibition of the 
control HPRT activity, nor was there activation of the variant enzyme 
activity under these conditions. Although the mixture contained 
more than three times the haemolysate protein from T.K. than from 
the control, the HPRT activities contributed by both enzymes, was 
equal at the hypoxanthine concentration used. Therefore 
any HPRT inhibiting factor in the T.K. haemolysates should have 
been detected. Bakay and Nyhan (1972), have demonstrated the 
activiation of a number of variant HPRT activities by the enzyme 
activities from normal individuals. However, activation of the 
variant activities was only observed if the enzyme preparations 
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were preincubated under denaturing conditions or passed through a 
column. 
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Table 4 
Effect on HPRT activity of mixing haemolysates from the patient 
T.K., and a from a normal individual. The HPRT activity in a 
mixture of haemolysates from T.K. and a normal individual, was 
assayed after the mixture had been preincubated at 0°C for 30 
minutes. 
Enzyme 
Variant 
Control 
Mixture 
HPRT activity 
(µU/mg prot.) 
Measured Predicted 
283 
289 
986 
977 
383 
405 
396 
Protein 
(mg/assay) 
• 7 5 
.22 
.56 
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9. PARTIAL PURIFICATION OF HPRT 
9.1. Method 
The HPRT activities from haemolysates, obtained from T.K. and a 
normal individual, were partially purified on a DEAE anion exchange 
column (Agarwal et al 1978). DEAE-cellulose (Whatman) with the fines 
removed, was poured into a column, 30 x 1.5cm, and equilibrated 
with K2HPo4 (lmM, pH 7.4). The haemolysates were prepared by 
lysing washed red blood cells with cold, distilled water (1:1), 
and the stroma removed by centrifugation. The supernatant was 
diluted with K2HP04 (lmM, pH 7.4), and applied to the column at a 
rate of l.2ml/minute. The column was washed with 4 volumes of the 
buffer. The bound protein was eluted off the column with a salt 
gradient of lmM to SOOmM of K2HPo4 , pH 7.4, at a flow rate of 
25ml/hr, and fractions of 5ml were collected. The HPRT activity 
in each fraction was determined by the LaC1 3 precipitation assay 
(Johnson et a1 1977) and all fractions containing HPRT activity 
were pooled. The pooled fractions were stirred with 
hydroxyapatite (2g/100ml) for two hours, and filtered on a 
Blichner funnel. The filtrate was brought to 60% saturation with 
(NH4 ) 2so4 and the protein was precipitated overnight. The 
precipitate was redissolved in 2ml of SOmM tris-HCl, pH 7.4, and 
dialysed against two changes of 2 litres of SOmM tris-HCl, pH7.4, 
containing DTT (0.8mM). The HPRT activity in this dialysate is 
referred to as 'partially purified'. 
9.1 Results 
The protein bound to the column eluted in three major peaks: 
the HPRT activity of both the variant and control enzymes 
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eluted before the first protein peak, immediately after the gradient 
was started. The specific activity of the variant enzyme increased 
from 198 to 3600µU, an 18 fold purification. However only 8% 
of the enzyme activity was recovered, while there was a 60% recovery 
of the control enzyme. 
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Fig. 14. Autoradiographs of polyacrylamide. gel 
electropherograms of haemolysates from patient T.K., three Lesch-
Nyhan Syndrome f!tients and normal controls. HPRT activity was 
detected using C-labelled hypoxanthine and by selectively 
precipitating the product, IMP, with Lac13 • A) 9% polyacrylamide gel: lanes 1 and 2, two brothers with the 
Lesch-Nyhan Syndrome; lane 3, a third, unrelated, LeSd'l-Nyhan 
Syndrome patient; lane 4, control; lane 5, T.K. 
B) 5-20% polyacrylamide gel: lanes 1 and 5, T.K.; lanes 2 and 
4, normal control; lane 3, partially purified HPRT activity from 
T.K. 
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10. ELECTROPHORESIS OF RED BLOOD CELL HPRT 
- -- ---
---
10.1. Methods 
Haemolysates, prepared from the patient T.K. and a normal 
individual, were diluted 1:10 with cold, distilled water and were 
mixed with an equal volume of 50% glycerol, lM tris-HCl, pH 7.4, 
and bromophenol blue and a sample of 100µ1 was applied to the gel. 
Undiluted haemolysates from three patients with the Lesch-Nyhan 
Syndrome (blood by courtesy of Prof. T. Jenkins, Dept. of 
Genetics, University of the Witwatersrand), were treated in a 
similar manner. The samples were electrophoresed for 20 hours at 
20 mA and 150 V, at 4°C. The HPRT activity present in the gels, 
was detected by placing a sheet of DEB! paper on the gel, and adding 
10ml of staining buffer, and incubating at 37°C for 1 hour. 
The staining buffer consisted of 50mM tris-HCl, pH 7.4, 4mM 
Mgso4 , l.4mM PP-ribose-P, and 14µM 
14c-hypoxanthine (55mci/mmol). 
The 14c-IMP that was formed in the gel, was precipitated with Lac13 
(O.!M) for 2 hours. The unreacted 14c-hypoxanthine was washed out 
of the gel overnight. The gel was dried between two layers of 
dialysis membrane, and the 14C-IMP was detected by autoradiography 
at -20°C for 72 hours. The 14c-IMP bound to the DEB! paper, was 
detected in a similar manner after the unreacted substrate had 
been washed off the paper with 25 litres of distilled water. The 
autoradiographs obtained by these methods were of a similar 
quality. 
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10.2. Results and Discussion 
The variant and control HPRT activity migrated for the same distance 
during the electrophoresis in a 9% polyacrylamide gel (Fig. 14a), 
whereas the activity from patients with the Lesch-Nyhan Syndrome 
migrated further. In addition the activity from one of these 
patients, unrelated to the other two, had a slower migrating 
component. The rapid migration of HPRT activity from patients 
with the Lesch-Nyhan Syndrome has previously been described 
(Bakay and Nyhan 1972). When electrophoresed in a 5-20% gradient 
gel the variant HPRT activity migrated more slowly than the 
control activity (Fig. 14b). Both the variant and control 
activities consisted of at least three components, while in the 
partialy purified form of the variant activity only the fastest 
moving component was visible. The heterogeneity of the HPRT 
activity in haemolysates has been described before (Arnold and 
Kelley 1971, Bakay and Nyhan 1972). The electrophoretic mobility 
of the variant and control enzyme activities differed in a 
polyacrylamide gradient gel, where differences in molecular size 
may be expected to play a greater role in determining the rate 
of migration of the protein, than the charge. 
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SECTION 2 
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11. EXPERIMENTS WITH CULTURED CELLS 
11.1. Materials 
The following radioactive substrates were obtained from The 
Radiochemical Centre, Amersham: [a-14~-hypoxanthine (55mci/mmol), 
[G- 3IiJ-hypoxanthine (l.2Ci/mmol), [a-14~-guanine sulphate 
(SlmCi/mmol), [a-3H]-guanine sulphate (7Ci/mmol), [ 14ccil-formic 
acid sodium salt (60.3mCi/mmol), ~-14cJ-adenine (296mCi/mmol), 
[methyl-3H]-thymidine (47Ci/mmol), and L-~,s-3ril-leucine 
(52Ci/mmol). The biochemicals hypoxanthine, guanine, adenine and 
thymidine, as well as the purine analogues 6-thioguanine and 
8-azaguanine, were obtained from Sigma. Mycophenolic acid was a 
gift from Lilly Research Laboratories. Amethopterin sodium 
(Methotrexate), was obtained from Lederle Laboratories. The 
'purine-free' FlO was a gift from Flow Laboratories, while the 
other media and the foetal calf serum were obtained from Gibco Europe 
or Flow Laboratories. The transformed lymphoblast cell lines, 
Ll06 and Ll07, were obtained from The Human Genetic Mutant Cell 
Repository, New Jersey. 
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11.2 Methods 
11.2.1. General 
All cells were grown in a Hotpack co2 incubator at 37°C with a 
relative humidity of 90% and co2 concentration of 4%. The medium 
used was Ham's FlO, supplemented with 15% foetal calf serum. Long 
term cultures were maintained in the absence of antibiotics to 
minimise the risk of mycoplasma contamination and were screened for 
such contamination every 3 to 4 months. Antibiotics, when used, 
were sodium benzyl penicillin (30µg/ml), streptomycin sulphate (SOµg/ml) 
and neomycin sulphate (SOµg/ml). 
11.2.2. Establishment of EBV-transformed lymphoblast cultures 
Permanent B-lymphoblast cell lines were established from the 
patient's peripheral blood by incubating the mononuclear cells, 
obtained by a modification of the method of Boyum (1968), with 
medium containing Epstein-Barr Virus (EBV). Five to ten 
millilitres of heparinised or EDTA blood was placed on 7ml of 
Ficol-Paque (Pharmicia) in a 15ml tube and centrifuged at 1000g for 
15 minutes at room temperature. About 2ml of the fluid at the 
plasma/Ficol-interface, containing mostly mononuclear cells and 
platelets, was removed. The cells were pelleted and washed once 
with 1ml of medium. This wash removed most of the contaminating 
Ficol-Paque, as well as a large number of the platelets. The 
cells were resuspended in 3ml of EBV-medium and incubated in 25cm2 
tissue culture flasks. The incubated cells consisted of a mixture 
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Fig. 15. Appearance of transformed lymphoblasts in a stock 
culture. The cells can be seen growing singly or in colonies 
(Magnified lOOx). 
of B-lymphocytes, T-lymphocytes and macrophages. The two latter 
cell-types survived for approximately 2 weeks in culture, while 
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the transformed B-lymphoblasts could be seen growing in suspension, 
singly or in colonies of 3 cells or more, after 7 to 30 days. 
No fresh medium was added during the first week of incubation, 
after that aliquots of 2ml of medium were added at 3 day intervals 
until the transformed cells divided rapidly. Aliquots of 
medium were removed and replaced with fresh medium. When the 
transformed lymphoblasts reached a density of 100-400xl03 /ml, half 
of the cells were transferred to other flasks. Care was taken to 
avoid over-diluting the cells, as this inhibited their growth rate. 
The medium of the rapidly growing cells was changed on alternate 
days. The cells were resuspended by gentle agitation, and half 
of the medium was replaced by an equal volume of fresh medium. 
The cell density was maintained at between 100-400xl03/ml. The 
appearance of cultured, transformed lymphoblasts is shown in Fig. 15. 
11.2.3. Preparation of medium containing EBV. 
Marmoset B95.8 cells were a gift from Dr. L. Wilson, Dept. of 
Immunology, u. c. T. These leukocytes secrete large amounts of 
EBV into their growth medium {Miller and Lipman 1973). Medium for 
transforming B-cells was prepared as follows: B95.8 cells were 
grown in large tissue culture flasks until they were confluent 
{unlike human transformed B-cells, they adhere to the culture 
flasks). The medium was replaced with 15ml of fresh medium and 
the cells were grown in this medium for a week. The medium was then 
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centrifuged at 3000 rpm for 10 minutes and filtered through a 
Millipore filter ( 0.45µ pore size) to remove any marmoset cells. 
The EBV-containing medium was diluted with an equal volume of 
fresh medium and used to transform the human, peripheral B-cells. 
11.2.4. Establishment of fibroblast cultures. 
A sterile, skin biopsy (3x3mm), was taken from the forearm of the 
patient, placed into culture medium, and transported to the tissue 
culture laboratory. The biopsy was cut up into smaller sections 
(less than lxlmm). These were placed under glass coverslips in 
35xl0mm petri dishes containing 2ml of medium and antibiotics. 
After 7-14 days the first fibroblasts appeared, a week later 
they had increased in number sufficiently for the coverslip to be 
removed. The cells were dispersed by trypsinisation, resuspended 
in fresh medium, and transferred to a second petri dish. The 
dispersion was necessary to minimise the contact inhibition of the 
fibroblasts. When the cells reached confluence they were 
trypsinised and transferred to a 25cm2 tissue culture flask. This 
was defined as the first passage. Cells were passaged when 
confluent (3:1 split ratio). The medium was changed every 3-4 
days. Early passage cells were frozen in fresh medium, containing 
10% glycerol and stored in liquid nitrogen until needed. 
11.2.s. Microscopy. 
The visual appearance of the cells was monitored daily, using 
phase contrast, with an inverted microscope (Nikon). 
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11.2.6. Determination of lymphoblast cell number in stock cultures 
The number of lymphoblasts was determined by counting samples of 
the cells in aliquots of medium, diluted 1/100 or 1/200 with 
'Isoton' (Coulter Electronics, s.A.), on a Coulter Counter Model Z 
(Coulter Electronics, Inc. Hialeah, Florida). The settings were 
selected to exclude the small vesicles, formed by the cells 
from being counted. 
11.2.7. Protein determination 
The protein concentration in the fibroblast culture wells was 
determined by a modification of the method of Lowry et al (1951), 
with BSA as the standard. 
11.2.8. Lymphoblast DNA extraction 
Lymphoblast DNA was extracted by the method of Kunkel et al 
(1977). The cells were washed three times with 1ml of cold, 0.9% 
NaCl and resuspended in 1ml of lysis buffer (0.32M sucrose, SrnM 
MgC1 2 , 1% triton X-100 and lOrnM tris-HCl, pH7.6). After lysis the 
insoluble material was pelleted and resuspended in 200µ1 of cold 
saline/EDTA (75rnM NaCl, 25rnM EDTA, pHB.O), and 20µ1 of 10% SDS was 
added. Ten microlitres of pronase (lOmg/ml) was added and the 
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samples incubated for 1 hour at 37°C. After digestion, 20µ1 of 
herring sperm DNA was added as a cold carrier, and 10µ1 of SM 
sodium perchlorate. Two hundred microlitres of phenol was mixed 
with the samples. After centrifugation, the upper aquous layer was 
extracted twice with 200µ1 of chloroform/octanol (24:1), and the 
DNA was precipitated overnight with 500µ1 of absolute ethanol at 
-20°C. The precipitated DNA was redissolved in 100µ1 of tris/EDTA 
(lOmM tris-HCl and lmM EDTA, pH7.8), at 37°C for 15 minutes. All 
extractions were carried out at room temperature in 2ml Eppendorf 
tubes. Centrifugation was done in an Eppendorf Centrifuge 5412, 
for 3 minutes. 
11.3. Designation of the lymphoblast cell lines. 
The origin of the various, transformed B-lymphoblasts and their 
designation was as follows: 
Patient T.K. 
Patient with the Lesch-Nyhan Syndrome 
Mother of the patient with the Lesch-Nyhan Syndrome 
L45 
Ll06 
Ll07 
Cell lines used as controls were acquired from patients with 
disorders not affecting their purine metabolism, for example L59 
was aquired from a patient with the Sickle Cell Trait 
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11.4. Selective media experiments. 
11.4.1. Transformed lymphoblasts. 
11.4.1.1. Method 
Lymphoblasts for selective media experiments were taken from stock 
cultures. The number of cells per millilitre of the stock 
cultures was determined, and aliquots containing approximately 
150 000 cells, were centrifuged in culture tubes (Falcon 2054 with a 
cap). The cells were resuspended in 0.5ml of medium, 
containing the desired selective agent. The initial number of 
cells was checked by counting the cells in 0.1ml of the medium. 
The medium was changed every 3-5 days, and the number of cells was 
determined as has been described. These cultures were generally 
continued for two weeks. Reference cultures of each cell line, 
maintained under the same conditions with the same medium changes, 
were used to determine cell growth in the absence of selective 
agents. Initially all experiments were performed in medium 
containing hypoxanthine and thymidine, but were repeated in FlO 
medium, without these constituents, when this became available. 
Their presence or absence was not found to influence the actions 
of the selective agents. Undialysed, foetal calf serum was used in 
all these experiments, as it was found that the lymphoblasts did 
not grow well in medium containing dialysed serum. Each 
experiment was performed in duplicate. 
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11.4.1.2. Evaluation of cell viability 
The viability of the lymphoblasts in selecive media was 
demonstrated by their ability to grow in such media. However, the 
incorporation of 3H-thymidine into TCA precipitable material was 
used as an additional index of lymphoblast viability. After the 
lymphoblasts had been cultured in the selective medium for 10-14 days 
the number of cells per tube was calculated from a sample of 
0.1ml of the medium. The remaining cells were pelleted and 
resuspended in 0.5ml of fresh medium, without any selective 
agents, and cultured overnight in the presence of 1 µCi/ml of 
3H-thymidine. The incorporation of tritium label into DNA was 
determined by precipitating the DNA with 5% TCA onto GF/C circles 
as described for the double lable experiments (see 11.5). The 
amount of tritium incorporated into the precipitable material was 
found to correlate with the cell number. 
11.4.1.3. Results 
11.4.1.3.1. HAT-medium 
HAT-medium consists of hypoxanthine, aminopterin and thymidine. 
Aminopterin inhibits de nova purine synthesis, as well as the 
formation of thymidine from dUDP, and therefore makes cells dependent 
on the salvage of hypoxanthine and thymidine for their purine and 
pyrimidine requirements (Littlefield 1964). The salvage of 
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Table 5 
The effect of HAT-medium on transformed lyphoblast growth. 
The% change in the number of cells, cultured for 13 days in the 
presence of the various components of HAT-medium, is shown for 
L45 and for a control cell line. 
Medium 
FlO 
FlO+ Aminopterin 
FlO+ Aminopterin 
+ Thymidine 
(lOµM) 
(lOµM) 
(400µM) 
FlO+ Aminopterin (lOµM) 
+ Hypoxanthine (200µM) 
FlO+ Aminopterin 
+ Hypoxanthine 
+ Thymidine 
FlO+ Aminopterin 
+ Guanine 
FlO+ Aminopterin 
+ Guanine 
+ Thymidine 
(lOµM) 
(200µM) 
(400µM) 
(lOµM) 
(lOOµM) 
(lOµM) 
(lOOµM) 
(400µM) 
% Change in cell-number 
L59 
+500 
+200 
+475 
+200 
+425 
+125 
+175 
L45 
(T.K.) 
+650 
- 75 
- 75 
- 75 
- 75 
- 75 
- 60 
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Table 6 
The growth of transformed lymphoblasts in HAT-medium. 
The% change in the number of cells, cultured for 12 days in FlO 
medium with additional hypoxanthine (200µM), and thymidine 
(400µM), in the presence of aminopterin, is shown for L45 and as 
well as number of control cell lines. 
Cell Line Medium 
Purine Containing Purine Free 
L45 
(T.K.) 
L59 
L57 
Ll07 
FlO FlO+ HAT 
+375 - 75 
+300 - 75 
+550 +425 
+375 +375 
-
FlO FlO+ HAT 
+350 - 50 
+850 - 40 
+100 + 60 
+550 +475 
The'purine-free' medium is prepared without hypoxanthine and 
thymidine, while the 'purine-containing'medium contains 30µM 
hypoxanthine and 3µM thymidine. 
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Table 7 
The effect of HAT-medium on 3H-thymidine uptake by transformed 
lymphoblasts. Lymphoblasts were cultured in HAT-medium for 11 
days. They were then cultured for 17 hours in the presence of 
lµCi/ml of 3H-thymidine and the incorporation label into TCA 
precipitable materal was determined. 
Cell Line 
L45 
(T.K.) 
L46 
L43 
L31 
dpm x10 2 
FlO FlO+HAT 
140 0.9 
270 486 
170 212 
508 831 
Cell Number x10 3 
FlO FlO+ HAT 
151 31 
316 340 
134 110 
324 275 
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Fig. 16. Effect of selective media on the growth of transformed 
lymphoblasts. Transformed lymphoblasts were cultured for 14 days 
in medium containing: ( + ), no additions: (~ ), HAT: ( • ), 
thioguanine. L45, cells from T.K.: Ll06, cells from a patient 
with the Lesch-Nyhan Syndrome: Ll07, cells from the mother of 
the patient with the Lesch-Nyhan Syndrome. 
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Fig. 17. Incorporation of 3H-thymidine into the TCA 
precipitable material of transformed lymphoblasts after they had 
been cultured in HAT-medium for 11 days. The cells were 
resuspended in medium containing H-thymidine (lµCi/ml) and the 
radioactivity incorporated into TCA precipitable material after 
17 hours, was determined. Reference cultures of each cell line 
were maintained under similar culture conditions without HAT-
medium. L45, cells from T.K.; L46, L43, and L31, cells from 
normal controls. 
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hypoxanthine is dependent on a normal HPRT activity, and that of 
thymidine is dependent on thymidine kinase activity. A deficiency 
in either of these enzyme activities results in the failure of 
the cells to grow in HAT-Medium. The effect of culturing 
lymphoblasts in the presence of aminopterin is shown in Table 5. 
The rate of increase in the number of the control lyphoblasts over 
a period of 13 days, was reduced, while an actual reduction in the 
number of the L45 lymphoblasts was observed. The effect of 
aminopterin on the control cell line was reversed by the presence 
of hypoxanthine and thymidine in the medium, while that on the L45 
cells was unchanged. The FlO medium used in this experiment was 
not entirely free of hypoxanthine, the addition of thymidine alone 
was therefore adequate to reverse the effects of the aminopterin on 
the control cell line. The effects of culturing the L45 and Ll06 
lymphoblasts in HAT-medium, are shown in Table 6 and in Fig. 16. 
While neither of these cell lines was able to grow, the growth of 
the control cell lines was maintained at a similar rate to that of 
the cells cultured in the absence of HAT-medium. The viability of 
the lymphoblasts after being cultured in HAT-medium, was also 
determined by their ability to incorporate 3H-thymidine into TCA 
precipitable material. The control cells grown in HAT-medium, 
showed an increased ability to incorporate 3H-thymidine into TCA 
precipitable material when compared with cells cultured in the 
absence of HAT-medium (Table 7 and Fig. 17). The L45 cells, 
however, showed a marked reduction in the 3H-thymidine uptake 
after being cultured in HAT-medium. The absence of an enhanced 
3H-thymidine uptake, and reduction in the number of cells, 
demonstrated the inability of the L45 lymphoblasts to survive in 
HAT-medium. 
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11.4.1.3.2. GAMA-medium 
GAMA-medium consists of guanine (200µM), adenine (lOOµM), 
mycophenolic acid (6µM), and azaserine (lOµM), and may be used as 
an alternative to HAT-medium (Liskay and Patterson 1979). 
Azaserine blocks de novo purine synthesis, while mycophenolic acid 
inhibits the formation of GMP from IMP by inhibiting the activity 
of IMP dehydrogenase (Franklin and Cook 1969). In the presence of 
these inhibitors, cells are made dependent on the salvage of 
adenine by APRT for the formation of adenine nucleotides, and on 
the salvage of guanine by HPRT for GMP formation. Therefore both 
adenine and guanine must be present in the medium containing 
azaserine and mycophenolic acid for the cells to survive. If 
hypoxanthine were to be substituted for adenine in the medium, the 
cells would have to form adenine nucleotides from IMP, and would 
be dependent on the salvage activity of HPRT alone. The effects 
of the various components of GAMA-medium on the growth of 
transformed lymphoblasts is shown in Table 8. Both azaserine and 
mycophenolic acid reduced the number of the L45 and of the control 
cells over an 8 day culture period. While the effect of 
mycophenolic acid on the growth of the control cell line was 
partialy reversed by guanine, this was not so for the L45 
lymphoblasts. The effects of azaserine on the growth of the cells 
was not reduced by the presence of hypoxanthine, guanine, or 
adenine. Both cell lines failed to grow in the complete GAMA-
medium, as well as when hypoxanthine was substituted for adenine. 
The failure of the complete GAMA-medium to differentiate between the 
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Table 8 
The effect of GAMA-medium on transformed lymphoblast growth. 
The% change in the number of cells, cultured for 8 days in the 
presence of the various components of GAMA-medium, is shown for 
L45 and for a control cell line. 
Medium % Change in cell number 
(FlO) 
L45 L57 
(T.K.) 
No additions +80 +180 
+Azaserine (lOµM) -60 -40 
+Mycophenolic acid (6µM) -60 -50 
+Mycophenolic acid (6µM) -60 +60 
+Guanine (200µM) 
+Mycophenolic acid (6µM) -55 -50 
+Hypoxanthine (200µM) 
+Mycophenolic acid (6µM) -70 -60 
+Adenine (lOOµM) 
+Mycophenolic acid (6µM) -60 -60 
+Azaserine (lOµM) 
+Azaserine (lOµM) -60 -50 
+Guanine (200µM) 
+Azaserine (lOµM) -60 -10 
+Hypoxanthine (200µM) 
+Azaserine (lOµM) +10 -10 
+Adenine (lOOµM) 
+Guanine (200µM) -70 -25 
+Adenine (lOOµM) 
+Mycophenolic acid (6µM) 
+Azaserine (lOµM) 
(GAMA) 
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Table 9 
A) The reversablilty of the effects of azaserine by adenine, 
hypoxanthine and guanine. The% change in the number of cells, 
cultured for 11 days in the presence of azaserine and various 
combinations of purine bases, is shown for L45 and for a control 
cell line. 
Medium % Change in cell number 
(FlO) 
L45 L57 
(T.K.) 
No additions +500 +500 
+Azaserine (lOµM) +200 + 50 
+Guanine (200µM) 
+Adenine (lOOµM) 
+Azaserine (lOµM) - 75 +150 
+Guanine (200µM) 
+Hypoxanthine (200µM) 
+Azaserine (lOµM) +125 + 25 
+Hypoxanthine (200µM) 
+Adenine (lOOµM) 
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Table 9 
B) The effect of the concentration of azaserine on the growth of 
a transformed lymphoblast cell line. The% change in the number 
of cells, cultured for 8 days in the presence of azaserine or 
azaserine with hypoxanthine (200µM) and adenine (lOOµM), was 
determined. 
Azaserine 
concentration 
Nil 
lOµM 
5µM 
lµM 
0.5µM 
O.lµM 
% Change in number of cells grown in 
FlO medium containing: 
Azaserine 
(only) 
+350 
- 40 
+100 
+250 
+350 
+375 
Azaserine, 
Hypoxanthine & Adenine 
- 40 
+100 
+250 
+300 
+325 
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Table 10 
The substitution of aminopterin and thymidine for azaserine in 
GAMA selective medium. The% change in the number of cells 
cultured for 11 days in the presence of mycophenolic acid (6µM), 
and either azaserine (lOmg/ml) or aminopterin (lOµM) and 
thymidine (400µM), was determined in the presence of various 
combinations of the purine bases, guanine (200µM), adenine 
(lOOµM), and hypoxanthine (200µM). 
Medium 
(FlO) 
No additions 
+Guanine 
+Adenine 
+Mycophenolic 
+Azaserine 
+Guanine 
+Hypoxanthine 
+Mycophenolic 
+Azaserine 
+Guanine 
+Adenine 
+Mycophenolic 
+Aminopterin 
+Thymidine 
+Guanine 
+Hypoxanthine 
+Mycophenolic 
+Aminopterin 
+Thymidine 
acid 
acid 
acid 
acid 
% Change in number of cells 
L45 
(T.K.) 
+500 
- 75 
- 75 
- 75 
- 75 
Ll06 L57 L59 
(HPRT-) 
+225 +500 +400 
- 65 +75 - 10 
+125 
- 65 +425 +350 
+450 
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Fig. 18. Effect of GAMA-medium and modified GAMA-medium, on 
the growth of transformed lymphoblasts. ( + ), no additions; ( *), GAMA-medium; ( • ) , modified GAMA-medium, in which 
azaserine was replaced with aminopterin. L45, cells from 
T.K.; Ll06, cells from a patient with the Lesch-Nyhan Syndrome; 
L59, cells from a normal control. 
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L45 and control lymphoblasts was further investigated. 
Lymphoblasts were cultured in the presence of azaserine and 
various combinations of the bases; hypoxanthine, guanine, and 
adenine (Table 9, a). The effects of azaserine could not be fully 
reversed in either cell line. The effect of the concentration of 
azaserine on the growth of the lymphoblasts is shown in 
Table 9, b. The rate of growth of the lymphoblasts was reduced at 
concentrations of above 0.5µM of azaserine. The presence of 
hypoxanthine and adenine in the culture medium could not reverse 
the effects of azaserine at any concentration. The toxicity 
of azaserine to the lymphoblasts therefore appears to be due to other 
effects of the inhibitor, and not only due to its inhibition of 
de novo purine synthesis. When aminopterin was substituted for 
azaserine, and the medium supplemented with thymidine, the growth 
of the control cell line was restored to normal by a combination 
of guanine and hypoxanthine, or of guanine and adenine (Table 10 & 
Fig. 18). Both the L45 and Ll06 lymphoblasts failed to grow in 
these modified media. Therefore, while the modified 'GAMA-medium' 
could differentiate between the control cell lines and the 
HPRT-deficient cell lines, GAMA-medium could not. 
11.4.1.3.3. Purine analogues 
The purine base analogues, thioguanine (6-thioguanine) and 
azaguanine (8-azaguanine) are converted to their respective 
nucleotides by the activity of HPRT (Kelley and Wyngaarden 1983). 
These analogue nucleotides are able to inhibit RNA and DNA 
synthesis. In cells lacking HPRT activity, these toxic nucleotides 
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Table 11 
The effects of thioguanine and azaguanine on transformed 
lymphoblast growth. The% change in the number of cells, 
cultured for 8 days in the presence of thioguanine (lOµg/ml) or 
azaguanine (40µg/ml) was determined. The ability of the cells 
to incorporate 3H-thymidine into TCA precipitable material was 
also determined. 
Medium 
(FlO) 
No additions 
+Thioguanine 
+Azaguanine 
% Change in cell number 
L45 
(T.K.) 
+134 
+272 
+ 98 
L46 L39 
+266 +142 
- 10 - 10 
- 50 - 70 
dpm 3H-thymidine 
incorporated 
( xl 0-2 ) 
L45 L46 L39 
184 449 178 
142 1.4 7.1 
74 1.1 1.2 
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are not formed, and their growth is unaffected by the presence of 
the purine analogues in the culture medium. The ability of 
HPRT-deficient cells to grow in the presence of toxic purine 
analogues serves to distinguish them from cells containing HPRT 
activity. When the L45 lymphoblasts were cultured for 8 days in 
the presence of thioguanine (lOug/ml) or azaguanine (40ug/ml), 
the number of cells increased, while the number of cells in the 
control lymphoblast cultures decreased (Table 11). Under the same 
conditions the control lymphoblasts incorporated less than 1000 dpm 
of 3H-thyrnidine into TCA precipitable material. The L45 
cells grown in the presence of thioguanine or azaguanine, 
incorporated 80% and 40% respectively, of the 3H dpm that were 
incorporated by L45 cells cultured in the absence of the purine 
analogues i.e. 18 400 dpm (Table 11). The L45 and Ll06 
lymphoblasts demonstrated a similar ability to grow in the 
presence of the purine analogues (Fig. 16). The resistance 
of the L45 lymphoblasts to the effects of toxic purine analogues 
was, therefore a further demonstration of their low intracellular 
HPRT activity. 
11.4.2. Skin fibroblasts 
11.4.2.1. Methods 
Fibroblasts from stock cultures were passaged into 24 well culture 
dishes (Costar, 16mm well diameter), at a density 1/3 of that of 
the stock cultures. The cells were incubated overnight in 2ml of 
fresh medium, which was replaced with selective medium the 
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Table 12 
A) The effect of selective media on the growth of skin 
firoblasts from T.K. and from a normal individual. The% 
increase in the protein content of the culture wells in which the 
skin fibroblasts were cultured for 10 days, in the presence of 
HAT-medium or thioguanine (lOug/ml), was determined. 
Medium 
(MEM) 
No additions 
+HAT 
+Thioguanine 
% Increase in protein content 
T.K. Control 
430 520 
110 470 
330 200 
B) The effect of selective medium on the growth of skin 
fibroblasts from T.K. and from a normal individual. The% change 
in the protein content of the culture wells in which the skin 
fibroblasts were cultured for 5 days in the presence of different 
concentrations of thioguanine, was determined. 
Medium % Change in protein content 
(MEM) 
T.K. Control 
+Thioguanine (lOug/ml) + 35 -70 
+Thioguanine (5ug/ml) + 25 -20 
+Thioguanine (2ug/ml) +160 +90 
98 
following morning. Enough wells for three time-points (in 
triplicate), were prepared. The growth of the cells at each time-
point was determined as follows: each well was washed three times 
with 2ml of cold normal saline and the cells were dissolved 
overnight in 1ml of lN NaOH and the protein concentration in each 
well was determined. The ratio of protein concentration on day 10 
to that on day 0, was used as an index of cell growth. 
11.4.2.2. Results 
The ratio of the protein content on day 10 to that on day 0, of 
the culture wells in which the skin fibroblasts were cultured in 
the presence of various selective media, is shown in Table 12. 
These ratios indicate that, while the fibroblasts obtained from 
T.K. do not grow as well as the control fibroblasts in HAT-medium, 
they grow better in the presence of thioguanine. 
11.4.3. Discussion 
The ability of cells to grow in selective media was used as a 
measure of their viability in these media. The viability of the 
lymphoblasts in selective media was also shown by the 
incorporation of 3H-thymidine into TCA precipitable molecules. 
Two types of selective media were used: 1) those which required 
the cells to salvage purines by the activity of HPRT for their 
survivial (HAT-, and GAMA-medium), and 2) those in which HPRT 
converted purine analogues into toxic nucleotides, preventing 
the growth of the cells (thioguanine and azaguanine). When 
cultured in these selective media, the L45 transformed 
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lymphoblasts derived from T.K., behaved in a similar manner to the 
Ll06 lymphoblasts, which are known to be deficient in HPRT 
activity. The growth behavior of both of these cell lines was 
different from that of the control lymphoblasts, which were 
obtained from normal individuals. The increased incorporation of 
3H-thymidine by the control cells cultured in HAT-medium is 
probably due to the induction of thymidine kinase activity (Fig. 16) 
and provides a convenient way of distinguishing viable from 
non-viable cells. The GAMA-medium (Liskay and Patterson 1979), 
failed to differentiate between the HPRT- a~d HPRT+ 
cells, since neither of these cell-types would grow in this 
medium. This was due to the azaserine (serine diazoacetate), 
which was used to inhibit purine synthesis de nova. When the 
azaserine was replaced by aminopterin in the modified GAMA-medium, 
the control lymphoblasts grew at a similar rate to that of the 
cells cultured in the absence of GAMA-medium (Table 10). 
Azaserine is a glutamine analogue which inhibits the three 
glutamine utilising steps in the de nova purine synthetic pathway 
(Wyngaarden and Kelley 1983). Since glutamine is a substrate in a 
number of other reactions, it is possible that azaserine could 
inhibit some of these reactions in the lymphoblasts. Therefore 
the growth of the lymphoblasts which are cultured for long periods 
in the presence of azaserine, is reduced, even though the 
inhibition of de nova purine synthesis is compenstated for by the 
purine salvage pathways in these cells. 
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11.s. Double Label Experiments 
The method used, is a modification of that of Rozen et al (1977). 
The incorporation of a 14c-labelled substrate of the metabolic 
pathway under investigation, into the TCA precipitable molecules 
of the cells, is determined. The incorporation of a 3H-labelled 
substrate, not of the same pathway, is also determined, and is 
used as an internal control. The ratio of 14c to 3H in the TCA 
precipitates obtained from cells with a defective index pathway, 
is lower than that obtained from the cells with an intact 
pathway. While this method of investigation does not demonstrate 
the enzyme defect directly, it does give qualitative information 
about the 'intactness' of the pathway in which the enzyme 
functions. An enzyme defect may therefore be indicated by the 
double label approach, but it would have to be demonstrated by 
other more direct methods. 
11.s.1. Lymphoblasts. 
11.s.1.1. Methods 
Approximately 200 000 cells were cultured in 0.5ml of fresh medium 
for 6 hours, before the radioactive substrates were added 
(generally lµCi/ml), and the cells were cultured for a further 
seventeen hours. After incubation the cells were pelleted and washed 
twice with cold, 0.9% NaCl, and placed on GF/C circles (Whatman 
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glass microfibre filters, 2.5cm). The filters were dipped 
into cold, 5% TCA in a 25ml beaker 4 times. The TCA was removed by 
dipping the circles into beakers containing ethanol and ether, 
respectively. The circles were placed into counting vials and 
allowed to dry for 30 minutes, and 10ml of 'Instagel' was added. 
The radioactivity was counted for 5 minutes in a Beckman LS-250 
scintillation counter. The ratio of 14c to 3tt was determined 
after the counts had been corrected for quenching and carry over 
of 14c into the tritium window. Each ratio was determined from 
duplicate cultures, except when, for statistical analysis, cultures 
were made in quadruplicate. In certain cases the cells were not 
precipitated onto GF/C circles, but mixed in Eppendorf tubes with 
0.5ml of cold, 5% TCA. The precipitate was washed with 0.5ml of 
ethanol, then by ether, and was dissolved in 100µ1 of lN NaOH. 
After being transferred into counting vials the alkali was 
neutralised with an equal volume of IN HCl and 10ml of 'Instagel', 
added. The ratio of 14c to 3tt was then determined as above. Both 
of these precipitation techniques gave compatible results. 
11.s.1.2. Results 
11.5.1.2.1. Hypoxanthine/guanine salvage 
The double label approach was used to evaluate the relative flux 
through the purine salvage pathway to that through the pyrimidine 
salvage pathway, in intact cells. The incorporation of 14c-purine 
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Table 13 
The relative incorporation of 14c-hypoxanthine to 3H-thymidine into 
TCA precipitable material. Lymphoblasts were cultured overnight 
in 0.5 ml of medium containing lµCi/ml of each of the labelled 
substrates, and the ratio of 14c to 3H was determined in the TCA 
precipitable material. 
Cell Line 14c dpm 3H dpm 14c/3H Mean+ S.D. 
(10 2 ) ( 10 2 ) 
L45 1157 24940 4.64 
(T.K.) 1141 27209 4.19 4.23+ 0.26 
1020 22689 4.49 
1079 27104 3.98 
Ll06 444 59627 o. 74 
(HPRT-) 394 64329 0.61 0.66+ 0.06 
528 78369 0.67 
400 62942 0.63 
Ll07 34888 77611 44.95 
35582 72946 48. 77 51.0 + 5.3 
-
26315 45839 57.4 
42640 80867 52. 72 
L59 79743 96936 82.26 
87240 140654 62.02 70.3 2+ 10.6 
83436 125096 66.69 
82529 132848 62.12 
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Table 14 
The relative incorporation of 14c-guanine to 3H-thymidine into TCA 
precipitable material. Lymphoblasts were cultured overnight in 
0.5 ml of medium containing lµCi/rnl of each of the labelled 
substrates, and the ratio of 14c to 3H was determined in the TCA 
precipitable material. 
Cell Line 14c dpm 3H d'pm 14c/3H Mean+ SD. 
( x10 2 ) (x10 2 ) 
L45 965 20716 4.66 
(T.K.) 655 15713 4.1 7 4.27+ 0.26 
725 17324 4.18 
660 16176 4.08 
Ll06 147 35094 0.42 
(HPRT-) 193 35187 0.55 0.41+ 0.11 
187 49689 0.37 
120 40365 0.30 
Ll07 13916 34041 40.88 
17258 34703 49. 73 46.33+ 4.95 
18780 43182 43.49 
12907 25190 51.24 
L59 30669 59070 51.91 
33095 70580 46.89 46.2 2+ 4.33 
24800 59420 41. 73 
22824 51430 44.38 
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Table 15 
The relative incorporation of 14c-hypoxanthine to 3H-leucine into 
TCA precipitable material. Lymphoblasts were cultured overnight 
in 0.5ml of medium containing lµCi/ml of each of the labelled 
substrates, and the ratio of 14c to 3H was determined in the TCA 
precipitable material. 
Cell Line 14c dpm 3H dpm 14c/3H Mean+ S.D. 
( x10 2 ) (xl0 2 ) 
L45 527 12793 4.17 
(T.K.) 473 11227 4.26 4.06+ 0.19 
434 11371 3.87 
453 11685 3.93 
Ll06 132 29955 0.49 
(HPRT-) 142 31867 0.49 0.51+ 0.03 
148 31196 0.52 
162 32102 0.55 
L57 14532 28937 50.26 
15501 30550 so. 79 51.05+ 0.65 
15860 30860 51.44 
15392 29675 51.7 
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Table 16 
The relative incorporation of 14c-guanine to 3H-leucine into TCA 
precipitable material. Lymphoblasts were cultured overnight in 
0.5ml of medium containing lµCi/ml of each of the labelled 
substrates, and the ratio of 14c to 3H was determined in the TCA 
precipitable material. 
Cell Line 14c dpm 3H dpm 14c/3H Mean+ S.D. 
(x10 2 ) (x10 2 ) 
L45 455 12814 3.6 
(T.K.) 536 14793 3.67 3.1+ 0.58 
389 14630 2. 71 
350 13950 2.56 
Ll06 36 35191 0.15 
(HPRT-) 40 35672 0.16 0.15+ 0.03 
28 34378 0.13 
54 39001 0.19 
L57 10481 27865 37.66 
11264 29086 38. 77 38.03+ 0.62 
11535 30879 37 .4 
12214 31957 38.27 
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base into TCA precipitable material, relative to the incorporation 
of 3H-thymidine, was determined by measuring the ratio of 14c to 
3H in the TCA precipitates, prepared from cells cultured in the 
presence of the labelled substrates. The relative incorporation 
obtained for 14c-hypoxanthine and 3H-thymidine is shown in Table 13, 
while that for 1 4c-guanine and 3H-thymidine is shown in Table 14. 
These results show that for hypoxanthine the L45 lymphoblasts 
incorporated between 6-8% of the relative 14c-counts of the 
control lines, while the cells from a patient with the Lesch-Nyhan 
Syndrome (Ll06), incorporated less than 1.3% of the control values. 
For guanine the respective values were 9% and<!% of the control 
values. In repeat experiments, the incorporation of label into the 
L45 cells varied between 3-11% for hypoxanthine and 3-17% for guanine, 
compared to that of the control cells. The amino acid, 3H-leucine, 
was used as the substrate for an alternative reference pathway. 
When the incorporation of 14c-labelled bases relative to that of 
3H-leucine was determined in TCA precipitable material, the L45 
cells were found to incorporate 8% of the relative counts of the 
control cells for both hypoxanthine and guanine. The values for 
the Ll06 cells were 0.4% and 1% respectively (Tables 15 & 16). 
11.5.1.2.2. Purine sythesis de novo 
A high rate of de nova purine synthesis is a biochemical feature 
of cells deficient in HPRT activity when they are cultured 
in medium containing hypoxanthine (Hershfield and Seegmiller 1975). 
Therefore the demonstration of a high flux through the de nova 
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synthesis pathway can be regarded as collateral evidence for 
such an enzyme deficiency. Formate is one of the small, precurser 
molecules of purines synthesised de novo. Radioactive formate 
has been used as a measure of the rate of de novo purine synthesis 
(Wyngaarden and Kelley 1983, Goron et a1 1979). The double label 
technique was used to measure the flux through the de novo purine 
synthesis pathway with 14c-formate, using 3H-thymidine as 
reference substrate. The exclusive utilisation of a radioactive 
substrate through a particular metabolic pathway is important in a 
double label experiment. If the substrate is utilised through 
more than one pathway, it is possible that the label will be 
incorporated into the TCA precipitable material through these 
alternative pathways (vectorial utilisation, Rozen et a1 1977). 
It was decided therefore, to measure the 14c to 3H ratio in DNA 
extracted from the cells to minimise the effects of the vectorial 
utilisation of formate on the ratio. The ratio of 14c to 3H, in 
DNA extracted from lymphoblasts grown in the presence of 
14
c-formate and 3H-thymidine for 17 hours, is shown in Table 17. 
The ratio of 14c to 3H was 20 times higher in the L45 cells than 
in the control cells (1.00 cf. 0.05). In repeat experiments the 
L45 cells had a ratio 8-12 times higher than that obtained in the 
control lymphoblasts. Azaserine was used in an attempt to modify 
the ratio of formate incorporation relative to that of thymidine. 
The effects of azaserine on the 14c to 3H ratio is shown in 
Table 18. Cells were cultured for 3 hours in the presence of 
azaserine (lOµM), before being resuspended in medium containing 
14c-formate, 3H-thymidine and azaserine and cultured for a further 
17 hours. The ratio of 14c to 3H was then determined in the DNA 
extracted from the cells. In both the L45 and the control cell 
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Table 17 
Purine synthesis de novo. Lymphoblasts were cultured for 17 
hours in the presence of 14c-formate (5µCi/ml), and 3H-thymidine 
(0.5µCi/ml) and the ratio of 14c to 3H was determined in the 
extracted DNA. 
Cell line 
L45 
(T.K.) 
L31 
Medium 
FlO 
FlO 
14c dpm 
18738 
17041 
606 
509 
18126 
17026 
12063 
13892 
1.03 
1.00 
0.05 
0.04 
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Table 18 
The effect of azaserine on de nova purine synthesis. Transformed 
lymphoblasts were precultured for 3 hours in the presence of 
azaserine {lOµM), and cultured for 17 hours in the presence of 
14c~ormate {5µCi/ml),and 3H~hymidine {0.5µCi/ml), and the ratio 
of 14c to 3H was determined in the extracted DNA. 
Cell line Medium 14c dpm 3H dpm 14c/3H MEAN 
L45 FlO 14209 45165 0.32 0.31 
{T.K.) 14299 49792 0.29 
L45 FlO+ 1920 5786 0.33 0.37 
{T.K.) azaserine 1747 4350 0.40 
L59 FlO 2241 88579 0.03 0.03 
2051 85001 0.03 
L59 FlO+ 1787 64072 0.03 0.03 
azaserine 2435 80723 0.03 
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Table 19 
Purine synthesis de nova. Transformed lymphoblasts, maintained in 
purine-free medium, were resuspended in 0.5ml of fresh medium 
containing 5µCi of 14c-formate and 0.5µCi of 3H-thymidine and 
cultured for 17 hours. The ratio of 14c to 3H was determined in 
the DNA extracted from the cells. 
Cell line 
L45 
(T.K.) 
Ll06 
(HPRT-) 
L61 
Lll4 
14c dpm 
5647 
6408 
9629 
16021 
484 
581 
1774 
1376 
3H dpm 14c/3H MEAN 
20567 0.28 0.27 
24626 0.26 
29822 0.32 0.31 
53630 0.30 
16243 0.03 0.04 
14788 0.04 
61804 0.03 0.03 
44636 0.03 
line the ratio did not change in the presence of azaserine. 
However, in the L45 cells a 7 fold reduction in the total 14c 
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and 3H incorporation was found. The control line did not show a 
similar reduction in total counts. The reduction in counts 
incorporated into DNA in the case of the L45 cells in the presence 
of azaserine was reproducible: the incorporated counts varied 
between 1 to 16% of the counts obtained in the absence of 
azaserine. This demonstrated the dependence of these cells on 
purines derived de novo for their DNA synthesis. The reduction in 
3H incorporation was probably secondary to the reduction in DNA 
synthesis. The ratios obtained with the L45 and Ll06 lyphoblasts 
were similar (Table 19). These experiments indicate that 
14c-formate incorporation into DNA is a good index of de novo 
purine synthesis, and that the L45 cells have an accelerated rate 
of purine synthesis de novo. 
11.5.1.2.3. Adenine salvage 
The activity of adenine phosphoribosyl transferase (APRT), has 
been found to be elevated in red blood cells deficient in HPRT 
activity. This increased enzyme activity is believed to be due to 
the higher intracellular concentrations of the substrate PP-ribose-P, 
which is common to both enzymes. The PP-ribose-P is thought to 
stablise APRT and reduce its rate of degradation in the cells 
(Greene et al 1970). The double label approach was used to determine 
if an increase in APRT activity could be demonstrated in transformed 
lymphoblasts. Lymphoblasts were cultured J.,. A~4-r$ in the 
presence of 14c-adenine and 3H-thymidine and the ratio of 14c to 
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Table 20 
The relative incorporation of 14c-adenine to 3tt-thymidine into 
TCA precipitable material. Transformed lymphoblasts were 
cultured in 0.5ml of medium containing 0.12µCi of 14c-adenine and 
2µCi of 3tt-thymidine for 4 hours and the ratio of 14c to 3H was 
determined in the TCA precipitable material. 
Cell Line 
L45 
(T.K.) 
L57 
14c dpm 
14265 
13524 
13481 
14047 
22543 
21529 
19741 
22488 
17342 
16176 
17162 
16957 
Mean+ s.D. 
( xl O) ( xlO) 
62597 2.28 
59014 2.3 
57118 2.37 
62588 2.25 
147472 1.53 
146769 1.47 
138896 1.43 
146485 1.54 
167137 1.04 
169498 0.96 
170155 1.01 
158826 1.07 
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Table 21 
The relative incorporation of 14c-adenine to 3H-thymidine into 
TCA precipitable material. Transformed lymphoblasts were 
cultured in 0.5ml of medium containing 0.12µCi of 14c-adenine and 
2µCi of 3H-thymidine for 4 hours and the ratio of 14c to 3H was 
determined in the the TCA precipitable material. 
Cell Line 
L45 
(T.K.) 
Ll06 
(HPRT-) 
Ll07 
Lll4 
L57 
L61 
14c dpm 
16254 
16961 
22782 
20844 
6674 
6650 
4833 
4784 
7377 
7361 
5995 
6633 
96267 
105785 
147257 
137893 
51972 
51545 
50560 
49383 
32028 
31180 
26571 
27047 
1.69 
1.61 
1.55 
1.52 
1.29 
1.3 
0.96 
0.97 
2.31 
2.37 
2.26 
2.46 
MEAN 
(xlO) 
1.65 
1.54 
1.3 
0.97 
2.34 
2.36 
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3H, was determined as has been described (Tables 20 & 21). In the 
first experiment shown, the ratio of 14c to 3H in the L45 cells 
was higher than that in the Ll06 and in the control cells (2.3, 1.5 
and 1.0 respectively). In the second, the ratio in the L45 cells 
was close to that in the Ll06 cells (1.65 and 1.54). These ratios 
fell within the range of those obtained for the control cells 
(1.3, 0.97, 2.34 and 2.36). Thus no difference in the APRT 
activity between the HPRT- lymphoblasts and control lymphoblasts, 
could be demonstrated. The ratios obtained for one cell line also 
varied from one experiment to another. This indicates that the flux 
through APRT was not constant. 
rl.5.2. Fibroblasts 
11.5.2.1. Method 
The fibroblasts were placed into 25cm2 flasks, and cultured 
overnight in 5ml of medium. The medium was replaced with 2ml of 
medium containing the radioactive substrates, and the cells, 
cultured for 3-4 hours. They were then washed with 5ml of cold, 
0.9% saline, trypsinised and transferred onto GF/C circles and 
treated with TCA, ethanol and ether and the ratio of 14c to 3H was 
determined as has been described for the lymphoblasts. 
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Table 22 
The relative incorporation of 14c-hypoxanthine or 14c-guanine to 
3H-thymidine into TCA precipitable material. Skin fibroblasts 
were cultured for three hours in 2ml of medium containing lµCi of 
each of the labelled substrates, and the ratio of 14c to 3H was 
determined in the TCA precipitable material. 
A) Hypoxanthine as the purine base. 
Cell Line 
from: 
T.K. 
Control 
B) Guanine 
Cell line 
from: 
T.K. 
Control 
as the 
Patient with the 
Lesch-Nyhan 
Syndrome 
14c dpm 
300 
265 
2800 
6245 
purine base. 
14c dpm 
1936 
650 
8720 
8948 
90 
50 
8410 
3676 
6079 
12376 
3H dpm 
21380 
15985 
70960 
81896 
26270 
18095 
0.045 
0.072 
0.463 
0.505 
14c/3H 
0.09 
0.04 
0.12 
0.11 
0.003 
0.003 
11.s.2.2. Results 
The ability of cultured skin fibroblasts, obtained from T.K. to 
incorporate 14c-purine bases relative to 3H-thymidine into TCA 
precipitable material, is compared with that of a control cell 
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line in Table.22. A lower ratio of 14c to 3H than that in the 
control cell line was obtained for both 14c-hypoxanthine and 
14c-guanine; this indicates a low intracellular activity of HPRT in 
the fibroblasts obtained from T.K. 
11.5.3. Discussion 
The double label experiments were used to measure the relative 
flux through the purine metabolising pathways, to that through a 
reference pathway (Rozen et al 1977). The ratio of 14c to 3H 
which was obtained with 14c-labelled hypoxanthine and guanine was 
low in both the L45 and Ll06 lymphoblasts, when either 
3H-thymidine or 3H-leucine was used as the substrate for the 
reference pathway (Tables 13 to 16). This indicates that the 
utilisation of hypoxanthine and guanine in these cells was lower 
than that of the control cells. The 14c to 3H ratios obtained for 
the L45 and Ll06 lymphoblasts were less than 20% and 2%, 
respectively, to those found in the control cells. A reduced 
ulitisation of the purine bases was also found in the skin 
fibroblasts obtained from T.K. The relative incorporation of 
14c-formate to 3H-thymidine into the DNA of the L45 and Ll06 
lymphoblasts was 10-20 times higher than that found in the control 
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cells (Tables 17 to 19). This showed that the DNA of these cells 
contained a greater amount of purines derived from de nova 
synthesis than did the control cells~ this indicated a higher 
rate of de nova purine synthesis in these cells. The high rate of 
purine synthesis de novo in HPRT deficient cells appears to be a 
compensatory biochemical change enabling the cells to maintain 
their nucleotide levels as close to normal as possible 
(Zoref-Shani and Sperling 1980). The relative flux through the 
adenine utilising pathway was similar in all cell lines tested 
(Tables 20 & 21), and there did not apppear to be an elevation in 
APRT activity in the HPRT deficient cells. Similar findings have 
been reported for other cultured cells deficient in HPRT activity 
(Kelley and Wyngaarden 1983). The double label approach demonstrated 
that the L45 cells resembled the Ll06 cells, which were derived 
from a patient with the Lesch-Nyhan Syndrome, more closely than 
they did the cells derived from individuals with normal purine 
metabolism. 
11.6. Formation and release of 14c-hypoxanthine and 14c-guanine 
by transformed lymphoblasts cultured in the presence of 14c-formate. 
11.6.1. Method 
Cells deficient in HPRT activity have been shown to release 
greater amounts of 14c-hypoxanthine and 14c-guanine into their 
culture medium than the control cells do when cultured in the 
presence of 14c-formate (Gordon et a1 1979). This may be a more 
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sensitive indicator of a HPRT deficiency, than the incorporation 
of label into DNA. The release of hypoxanthine and guanine into 
the medium by the L45 and control lymphoblasts, was determined by 
analysing the medium from a 14c-formate/ 3H-thymidine double label 
experiment for the presence of 14c-labelled purine bases. The 
medium was deproteinated with 0.5ml of lN PCA. After 
centrifugation the supernatant was mixed with 100µ1 of SM K2co 3 , 
and the precipitate was removed by further centrifugation. The 
bases were concentrated by freeze-drying the samples twice and 
dissolving the residues in 500µ1 and 100µ1 of buffer (lmM KH2Po4 , 
pH3.0), respectively. The bases were separated by HPLC (Spectra-
Physics, Model 3500), using a reverse phase column (Spectra-Physics 
RP-8, lOµm), and a step gradient of methanol (0-10%) in buffer. 
The rate and pressure of elution were !ml/minute and 450-550psi, 
respectively. Formate eluted off the column first, followed by 
hypoxanthine. The guanine was eluted with the 10% 
methanol/buffer. Cold hypoxanthine and guanine were added to each 
sample as carriers, and aliquots of 50µ1 from each sample were 
applied to the column. After a delay of 30 seconds, fractions 
were collected into counting vials for 15 seconds each. After the 
elution of the hypoxanthine, the buffer containing the 10% 
methanol was started, and after another 30 second delay, further 
fractions were collected. The elution was monitored at 260nm. 
The fractions were mixed with 10ml of 'Instagel' and the 
radioactivity in the hypoxanthine and guanine peaks was 
determined. The recovery of the radioactivity placed on the 
column varied between 83-98%. Initial analysis of the samples by 
HPLC with a cation exchange column (Whatman sex, Partisil-10) was 
attempted, but failed to separate the formate and hypoxanthine. 
-./ 
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11.6.2. Results 
The release of hypoxanthine and guanine into the culture medium by 
cells grown in the presence of 14c-formate is shown in Table 23. 
The radioactivity in the hypoxanthine peak was twenty times higher 
in the medium of the L45 cells than that of the control cells 
(23 442 cf 1 174 and 1 278 dpm). For guanine no radioactivity above 
background was found in the media of the control cells, while 
1 990 dpm were obtained from the medium of the L45 cells. When the 
L45 cells were cultured in the presence of azaserine, the counts 
in the hypoxanthine peak were reduced to 1 610 dpm, and no counts 
above background were found in the guanine peak. Therefore the L45 
cells released more radioactive hypoxanthine and guanine into the 
culture medium than the control cells did, while the amount of 
radioactive bases found in the medium of the cells cultured in the 
presence of azaserine, was markedly reduced. This implies an 
increased production of radioactive bases from 14c-formate in the 
L45 cells, and an enhanced purine synthesis de novo. However, a 
proportion of the radioactive bases were released into the medium 
of the L45 cells due to a lack of salvage and of cycling of the bases 
in these cells, and not solely due to an increased synthesis de novo. 
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Table 23 
The purine synthesis de novo was measured by the release of 14c-
hypoxanthine and l4c-guanine by transformed lymphoblasts grown in 
the presence of 14c-formate. Lymphoblasts were cultured in the 
presence of lOµCi/ml of 14c-formate for 17 hours. The release of 
14c-hypoxanthine and 14c-guanine into the medium was determined 
by analysing the deproteinated medium on reverse phase HPLC and 
by measuring the radioactivity in the hypoxanthine and guanine 
peaks. Cells grown in the presence of azaserine (lOµM), were 
precultured for three hours in the presence of the inhibitor. 
Cell Line 
L45 
(T.K.) 
L45 
(T.K.) 
L49 
L59 
Medium 
FlO 
FlO+ 
azaserine 
FlO 
FlO 
N.D.= Nil detected 
14c dpm in 
hypoxanthine 
23442 
1810 
1174 
1278 
14c dpm in 
guanine 
1990 
N.D. 
N.D. 
N.D. 
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11.6.3. Discussion 
Normal cells have a similar rate of purine synthesis de novo when 
they are compared with HPRT- cells in purine-free medium (Gordon 
et al 1979). However, when they are cultured in medium containing 
hypoxanthine, their rate of purine synthesis de novo is reduced, 
while that of the HPRT- cells, remains high. Cells deficient in 
HPRT activity, release more hypoxanthine into the medium than do 
the control cells (Gordon et al 1979). This is due to the lack of 
cycling of the bases by HPRT activity and to the high rate of purine 
biosynthesis in these cells. The release of radioactively 
labelled bases into the medium, by cells cultured in the presence 
of 14c-formate, provides another indication of a lack of HPRT 
activity in the cells. The L45 lyrnphoblasts released twenty times 
as much radioactivity into the hypoxanthine fraction of their 
medium than the control cells did when cultured in the presence of 
14
c-formate (Table 23). This amount of radioactivity was greatly 
reduced when azaserine was added to the cultures. Therefore the L45 
lymphoblasts showed yet another feature of an intracellular HPRT 
deficiency. 
11.7. Relative utilisation of labelled hypoxanthine to labelled 
guanine. 
Assays of the HPRT activity in haemolysates prepared from T.K. by 
the continuous spectrophotometric assay, indicated that there was 
a discrepancy between the Vmax values obtained for hypoxanthine 
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Table 24 
Comparison of the salvage of hypoxanthine and guanine in intact 
lymphocytes. Transformed lymphocytes were cultured for 17 
hours in the presence of labelled hypoxanthine and guanine and 
the ratio of 14c to 3H was determined in the TCA precipitable 
material. 
A) Cells cultured with 14c-hypoxanthine (0.25µCi/ml), and 3H-
guanine, (!µCi/ml). 
Cell Line 
L45 
(T.K.) 
L49 
L59 
14c dpm 
437 
494 
264 
294 
7642 
6319 
3tt dpm 
4074 
4585 
2510 
2657 
71160 
55061 
B) Cells cultured with 14c-guanine 
hypoxanthine, (!µCi/ml). 
Cell line 14c dpm 3tt dpm 
L45 223 5190 
(T.K.) 173 4296 
L49 244 3586 
234 3457 
L59 5720 94124 
5160 97705 
0.108 0.108 
0.108 
0.106 0.108 
0.111 
0.108 
0.115 
(0.25µCi/ml), 
14c/3H 
0.044 
0.041 
0.069 
0.068 
0.061 
0.057 
0.112 
and 3H-
Mean 
0.042 
0.068 
0.057 
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and guanine. The former was similar to that of the control 
activity, while that for guanine was much lower than that of the 
control activity. To determine if these findings could be 
confirmed in intact cells, L45 lymphoblasts were cultured in the 
presence of labelled hypoxanthine and guanine and the ratio of 14c 
to 3a was determined in the TCA precipitable material. When 
14c-hypoxanthine and 3a-guanine were used, ratios of 0.1 were 
obtained for all the cell lines (Table 24, a). When the labels 
were reversed, ratios of 0.04, 0.068, and 0.05 were obtained for 
the L45 and the two control cell lines, respectively (Table 24, b). 
These results indicate that there is no major defect in the 
relative utilisation of hypoxanthine and guanine by the L45 
lymphoblasts. 
11.8. HPRT activity in transformed lymphoblast post-microsomal 
supernatants 
11.8.1. Method 
The HPRT activity was determined in lymphoblast post-microsomal 
supernatants, prepared by a method similar to that of Wilson et a1 
(1982). Approximately ten million cells were pelleted and washed 
twice with 1ml of 0.9% saline in 1ml Eppendorf tubes. They were 
resuspended in 500µ1 of 50mM tris-HCl, pH7.8, 150mM NaCl, and 
lysed by six cycles of freeze-thawing. Cells were frozen in an 
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Table 25 
HPRT activity in post-microsomal supernatants of transformed 
lymphoblasts. The HPRT activity was determined in post-
microsomal supernatants prepared from transformed lymphoblasts 
from the patient T.K. and normal controls. The enzyme activity 
was assayed at different concentrations of hypoxanthine and 
guanine. 
A) Hypoxanthine as substrate. 
Hypoxanthine 
(µM) 
60 
150 
400 
B) Guanine as substrate 
Guanine 
(µU) 
6 
15 
30 
L45 
797 
766 
1111 
L45 
967 
1112 
1319 
HPRT activity 
(µU/mg protein) 
Ll45 
9183 
10466 
20933 
HPRT activity 
(µU/mg protein) 
Ll45 
17027 
20833 
21655 
Ll41 
13122 
15242 
23482 
Ll41 
7818 
15261 
18214 
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ethanol/dry-ice mixture and thawed in a water-bath at 37°C. The 
intact cells together with most of the cellular debris from the 
lysed cells, were removed by centrifugation for 1 minute in an 
Eppendorf Centrifuge (5412). The supernatant was centrifuged for 
30 minutes at 100 OOOg in a Beckman Airfuge. The enzyme activity 
was determined in the supernatant, and the latter was diluted with 
the buffer to give approximately 50µU of enzyme activity per 20µ1 
aliquot. Enzyme activity was determined by the multiple end-point 
assay (Wohlhueter 1975) in the presence of lmg/ml BSA. 
11.a.2. Results 
The HPRT activity in post-microsomal supernatants prepared from 
the L45 and control lymphoblasts are shown in Table 25. The HPRT 
activity in the L45 lymphoblasts was substantially lower than that 
in the control cells over a wide range of substrate 
concentrations. The L45 lymphoblasts had activities varying 
between 3-4% of the control activities for hypoxanthine 
and 5-7% for guanine. The low intracellular activity of HPRT 
as indicated by the intact cell studies, therefore was 
substantiated by the low activities obtained in the cell post-
microsomal supernatants. 
11.8.3. Discussion 
The HPRT activity in the post-microsomal supernatants from the 
cultured lymphoblasts derived from T.K. was low compared with 
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that from control cells. The activity was less than 10% of that 
in the control cell supernatants at all purine base 
concentrations, and is in agreement with that demonstrated in the 
intact cells by the double label assays. 
11.9. Effect of extracellular purine concentration on the relative 
uptake of hypoxanthine. 
11.9.1. Method 
To determine whether substrate inhibition of HPRT activity could 
be demonstrated in the intact cells derived from T.K., 
double label experiments were performed at different 
concentrations of hypoxanthine. The relative molar 
incorporation of hypoxanthine to leucine into TCA precipitable 
material at each hypoxanthine concentration, was determined. The 
hypoxanthine concentrations in the medium ranged from 44µM to 
544µM. 
11.9.2. Results 
The relative incorporation of hypoxanthine relative to leucine, into 
TCA precipitable material, showed a slight increase with an increasing 
hypoxanthine concentration for the control cell lines. This 
indicated that the hypoxanthine utilisation was close to 
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Fig. 19. Effect of the extracellular h
YP.OXanthine concentration 
on the relative molar incorporation of
 ~~C-hypoxanthine to 3H-
leucine into the TCA precipitable mate
rial of transformed 
lymphoblasts. The cells were cultured 
in the presence of 
hypoxanthine at concentrations of betwe
en 44 to 544µM and the 
relative incorporation of 
14c-hypoxanthine to 3 H-leucine into TCA 
precipitable material, was determined. 
( • ), cells from a 
patient with the Lesch-Nyhan Syndrome;
 ( • ) , cells from T.K.; 
( <1111 ) , and ( a ) , cells from normal controls. 
saturation at the lowest concentration used (Fig. 19). The L45 
lymphoblasts incorporated 5% of the relative amount of 
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hypoxanthine to leucine, compared with the control cell lines at 
all the concentrations of hypoxanthine. Therefore no inhibition of 
hypoxanthine incorporation could be demonstrated. The Ll06 
lymphoblasts showed a relative increase in the incorporation of 
hypoxanthine from less than 1% to almost 6% of the values obtained 
for the control cell lines. This may reflect an altered Kso for 
hypoxanthine incorporation or the activation of a non-HPRT dependent 
system for hypoxanthine uptake in these cells. 
11.9.3. Discussion 
Studies on several mammalian cell lines have shown that the 
intracellular and extracellular hypoxanthine are in equilibrium 
with each other, and that the intracellular concentration of 
hypoxanthine is similar to that in the culture medium (Murz et al 
1979). A range of hypoxanthine concentrations in the culture 
medium was used to ascertain whether a reduction in the flux through 
the purine salvage pathways in the lymphoblasts, derived from T.K., 
occurred, and therefore to demonstrate substrate inhibition of the 
HPRT activity in these cells. However, no change in the 
incorporation of hypoxanthine in the L45 lymphoblasts, relative to 
that in the control cell lines, could be shown. It may be that 
the intracellular concentration of hypoxanthine did not increase 
sufficiently in the L45 cells for substrate inhibition to be 
demonstrated, or that the lymphoblast HPRT activity is 
not susceptible to substrate inhibition. 
11.10. Polyethylene glycol-induced cell fusion. 
11.10.1. Method 
Investigations into the nature of various inherited metabolic 
diseases have shown that patients presenting with similar 
biochemical disorders, may have different lesions at a 
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molecular level. This heterogeneity may result in lesions which 
are complementary to each other. An example of complementary 
molecular lesions can be found in Methylmalonic Acid Uria. Here 
deficiencies in methylmalonyl CoA mutase were shown to be due to 
either apoenzyme defects, or defects in the synthesis of the co-
factor, adenosylcobalamin (Rosenberg and Scriver 1980). The 
fusion of fibroblasts from a patient with an apoenzyme defect, 
with those from a patient with defective co-factor synthesis, has 
resulted in hybrid cells with a mutase activity approaching that 
of control cells (Gravel 1975). To investigate the possibility 
that the L45 and Ll06 lymphoblasts had complementary molecluar 
lesions, it was decided to fuse cells from both lines and to 
determine if any hybrid cells could survive in HAT-medium. The 
method used was that of Davidson et al (1976). Approximately ten 
million cells from each of the stock cultures were mixed in a 50ml 
centrifuge tube and pelleted. The cells were resuspended in 3ml 
of serum-free medium, transferred to the culture tubes, and were 
centrifuged at 1500 rpm for 3 minutes. The medimn was 
discarded and the tubes inverted on tissue paper for 1 minute to 
drain off the last few drops of medium. This was necessary to 
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prevent dilution of the polyethylene glycol (PEG). After all the 
medium had been removed, 50% PEG (0.5ml), was added to the cells 
over a period of 1 minute. While the PEG was added, the 
tubes were rolled gently to facilitate mixing. After incubation 
at 37°C for 1 minute, 0.5ml of 20% PEG was added and incubation 
was continued at room temperature. After 3 minutes the PEG was 
diluted with 2ml of serum-free medium and the cells were pelleted 
at 1500 rpm for 3 minutes. The cells were resuspended in 8ml 
of medium, divided into two 4ml fractions and the cells from each 
fraction were pelleted. One of the pellets was resuspended in 
10ml of HAT-medium and the other in 10ml of medium, and the cells 
were cultured in 25cm2 flasks for 4 weeks. The growth and 
appearance of the cells was monitored over this period. Reference 
cultures (isohybrids) of PEG-treated cells were prepared for each 
of the HPRT-deficient cell lines. Hybrids of control lymphoblasts 
were also prepared. The PEG and serum-free medium mixture was 
prepared as follows: 10 grams of PEG (M.W.1500, BDH) was 
autoclaved at 121°C for 15 minutes. The PEG was allowed to cool 
to 45°C and mixed with 10ml of pre-warmed, serum-free medium. 
11.10.2. Results 
The PEG-induced fusion experiments were designed to determine 
whether complementary biochemical defects existed between the two 
HPRT- lymphoblast cell lines, L45 and Ll06. After the cells from 
these two lines had been fused, they were divided into two 
fractions, one for culture in HAT-medium, while the other was 
maintained as a control culture. The cells in the control 
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cultures continued to grow rapidly, while those in the HAT-medium 
did not. No hybrid cell-clones appeared that could survive in 
HAT-medium. This indicated a lack of hypoxanthine salvage in 
these cells, and therefore no complementation between the two 
HPRT- cell lines. Cells from two control lymphoblast cell lines, 
fused and treated in a similar manner to the HPRT- cells, grew 
well in HAT-medium. The isohybrid HPRT- cells failed to grow in 
HAT-medium. 
11.10.3. Discussion 
Hybridization experiments with HPRT- and HPRT+ cells 
have demonstrated that there are at least two 
cistrons that can affect HPRT activity in cultured cells (Kelley 
and Wyngaarden 1983). It is possible that defects in either of 
these cistrons may be responsible for a lack of HPRT activity. 
Hybrid cells prepared from two different HPRT- cell lines, may 
develop adequate HPRT activity to survive in HAT-medium, if their 
defects are complementary. However, no such complementary defect 
appears to exist in the two HPRT- cell lines tested in this 
experiment. Similar studies with other HPRT- cells, may yield 
HPRT+ hybrids. 
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SECTION 3 
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12. PARTIAL HPRT-DEFICIENCY: A CASE REPORT 
12.1. Medical history 
T.K. has a history of repeated attacks of renal colic, the first 
occured at an age of 4. He was investigated for haematuria 
at 13 years of age, and again at 17 years. No records of the 
findings of these investigations are available. At 18 years he 
had his first attack of arthritis, which affected his great toes 
and one of his ankle joints. Since then he has had several 
attacks of arthritis, which have varied in intensity from mild 
discomfort in his toes, to severe gout. He has no history of any 
major illnesses, surgery or accidents. He is the only affected 
member of his family. He is married, with one daughter, and works 
as a book binder. 
12.2. Physical examination 
T.K. is slightly built, weighs 54kg and has no physical deformities 
(Fig. 20). There are no abnormalities of his cardiovascular, 
respiratory, gastro-intestinal or musculo-skeletal systems. 
Neurologicaly he has a symmetrical hyper-reflexia of his knees and 
ankles, and a fine nystagmus on sustained lateral gaze. His I.Q. 
is 66. Investigations into his genito-urinary system have shown 
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Fig. 20. Photograph of patient T.K. 
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that he has a normal left kidney, and a small, barely functioning 
right kidney with a bifid collecting system and clubbed calyces. 
The reduced function of his right kidney is secondary to the 
congenital abnormalities affecting that kidney, and is not related 
to his hyperuricaemia(Cassidy et al 1980). 
12.3. Laboratory investigations 
His serum urate fluctuates between 0.71-8.2 mmol/1 (reference 
range 0.12-0.5 mmol/1), and his urinary urate levels are between 
6.0-7.4 mmol/d (reference range 1.5-4.4 mmol/d), when he does not 
receive treatment. His urate clearance is 11 ml/minute. 
All his other serum biochemical parameters are within the 
reference limits for this laboratory. Haemotological 
investigations have shown no signs of macrocytosis. 
12.4. Treatment and clinical course 
At present he is being treated with allopurinol, 200mg twice daily, 
and citro soda, 2 g three times daily. With this treatment, his serum 
urate remains at about 0.45 mmol/1 and his urinary pH is about 6.8. 
However, he does not take his drugs when he is free of symptoms. 
He has had occasional attacks of arthritis, about once a year, 
and has had one attack of renal colic, since he has been on treatment. 
His failure to take his drugs is due to a complete 
lack of insight into the nature of his disease. 
There has been no change in his renal function in the last five 
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years, with the creatine clearance remaining between 80 and 100 
ml/minute. He has had one episode of an asymptomatic elevation in 
his serum creatine kinase (CK) activity. The CK activity reached 
a peak of 225 u/1 (reference range 0-50 u/1), and remained 
elevated for 4 months. The MB-isoenzyme was negative on 
electrophoresis and there were no other signs of cardiac 
involvement. There was a transient increase in his serum LDH 
activity to a peak of 388 U/L (reference rage 100-350 U/1), with a 
normal isoenzyme pattern. He remained entirely asymptomatic 
during this period. The CK activity returned to normal without 
any treatment, nor did he stop taking his allopurinol. The 
cause of the elevated CK activity was never established, but it 
was assumed to be due to a possible deposition of oxipurinol or 
of other purine crystals in his muscle tissue (Watts et al 1971). 
12.5. Discussion 
The presentation of T.K. with the complications of 
hyperuricaemia, is typical of a patient with a partial HPRT-
deficiency (Kelley and Wyngaarden 1983). The high daily urate 
excretion and normal urate clearance, indicate that he is a urate 
over-producer, and that his hyperuricaemia is not due to a renal 
mechanism. The HPRT activity in his red blood cells, 
is about 25% of the normal mean, and is typical of 
the activities found in patients with a partial HPRT-deficiency 
(Kelley and Wyngaarden 1983). His renal function has remained 
constant over the five years since the diagnosis of a partial 
HPRT-deficiency was made, and, provided that the episodes of renal 
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colic can be kept to a minimum, and any secondary bacterial 
infections prevented, it should not change. His treatment is 
complicated by his failure to take his drugs, and it is unlikely 
that anything can be done to improve his compliance. 
The cause of the transcient elevation in his serum CK activity 
remains unknown, but muscle injury due to crystal 
deposition remains a possiblity. The administration of 
allopurinol may elevate the intracellular levels of hypoxanthine 
and guanine in his cells and therefore, increase the degree of 
HPRT-deficiency by substrate inhibition. However this is a 
theoretical problem. Since his intracellular HPRT activity is 10% 
normal, a marked change in purine base concentration would 
be needed to inhibit the enzyme any further if substrate 
inhibition is the cause of the low activity, particularly as zero 
enzyme activity occurs only at an infinite substrate concentration 
in uncompetetive substrate inhibition (Cleland 1979). The beneficial 
effects of allopurinol in reducing his serum urate levels and 
in lowering the frequency of his attacks of gout and renal stones is 
far greater than the danger of increasing his intracellular purine 
base concentration. 
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13. SUMMARY AND GENERAL CONCLUSIONS 
The patient T.K. presented with the clinical features, typical of 
purine overproduction and a partial HPRT deficiency: uric acid 
lithiasis and gout. The interesting kinetic characteristics of 
the variant HPRT activity in his haemolysates would have 
been missed had it been assayed at only one substrate 
concentration. The variant enzyme activity in haemolysates showed 
substrate inhibition by the purine base substrates. This was 
responsible for the low HPRT activity observed in vitro, since there 
were no marked differences in the Km and Vmax values between the 
variant and control enzymes. The substrate inhibition of the 
variant enzyme resulted from the formation of a dead-end complex 
between hypoxanthine and an enzyme-PPi intermediate. Hypoxanthine 
and IMP can bind at the same site on the variant enzyme-PPi 
intermediate: the mechanism that prevents this from happening in 
the normal enzyme is unknown, but it may be that a conformational 
change takes place on the release of IMP, preventing the binding of 
hypoxanthine. The HPRT activities were assayed by a modification 
of the assay published by Wohlhueter (1975), taking into 
consideration the pH and magnesium dependence of the enzyme 
activity. An alternative kinetic assay (Giacomello and Salerno 
1977) was used in the initial characterisation of the variant 
enzyme: similar kinetic parameters for the variant and control 
enzyme activities were obtained with both assays. The variant 
enzyme activity was unstable in its partially purified form, and 
since no difference in the degree of substrate inhibition could be 
shown between the enzyme activity in haemolysates and the 
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partially purified activity, the former was used for the kinetic 
characterisation of the variant. A low HPRT activity was shown in 
cultured cells from the patient. The double label technique 
demonstrated a reduced flux through the hypoxanthine/guanine 
salvage pathway, relative to that through the thymidine or leucine 
pathways. The rate of purine synthesis de novo was higher in the 
transformed lymphoblasts from T.K. compared with that of control 
cells. This was shown by the double label approach, and by the 
release of labelled hypoxanthine and guanine into the medium. The 
APRT activity in the HPRT- cells was similar to that in the 
control cells. The behaviour of cultured cells obtained from T.K. 
and cells known to be defective in HPRT activity was similar in 
selective media. This included their inability to grow in 
HAT-medium or the modified GAMA-medium, and their resistance to 
the toxic effects of thioguanine and azaguanine. No substrate 
inhibition could be demonstrated in these cells despite the low 
HPRT activity, nor could a complementary biochemical defect 
between the two HPRT deficient cell lines, be shown. The HPRT 
activity in post-microsomal supernatants, obtained from the 
transformed lymphoblasts from T.K., was 10% of the control 
activity. 
Although these studies have shown this HPRT variant an interesting 
and unique enzyme, the molecular defect still has to be defined. 
This could be due to either a change in the primary structure, 
or to a secondary modification of the enzyme protein. 
Therefore protein structural studies, complemented by an analysis 
of the gene coding for the HPRT variant, have yet to be done. 
Note added in proof 
~ paper based o~ the kinetic characterisation and investigation 
into the mechanism of the substrate inhibition of the variant 
HPRT.act~vity presented in this thesis, has been accepted for 
publication in the Journal of Biological Chemistry. 
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